Società Prodotti Antibiotici SpA

Paris, October 28, 2021 Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1) Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC Specialty Care sales increased 20.2% with strong contribution from Dupixent® (+54.6% to €1,410 million) Vaccines up 16.5%, with record quarterly sales driven by differentiated flu vaccines and meningitis franchise recovery CHC increased 11.1% driven by growth of Pain care and Digestive Wellness categories General Medicines sales down 1.7% while transformation of business model supports core assets growth (up 4.5%) Q3 2021 business EPS(2) growth of 19.1% at CER driven by sales performance and efficiencies Business EPS(2) was €2.18, up 19.1% on a reported basis BOI margin reached 34.1% up 2.2 ppts reflecting improvement in Gross margin and continued expense management IFRS EPS was €1.85 (up 19.4 %) Progress on Corporate Social Responsibility strategy Carbon neutrality target accelerated to 2030; a 2050 net zero objective established Sanofi ranked #1 in the European pharma sector by ESG rating agency Vigeo Eiris (part of Moody’s ESG Solutions) Key milestone and regulatory achievements on R&D transformation Positive pivotal phase 3 readouts for Dupixent® in chronic spontaneous urticaria and infant atopic dermatitis (6 months to 5 years) Nexviazyme® approvals in U.S. and Japan Submissions of sutimlimab in the U.S. and olipudase alfa in Japan under the Sakigake pathway Acquisition of Translate Bio completed, first positive clinical data read-out validating the mRNA platform Full-year 2021 business EPS guidance revised upward(1) Sanofi now expects 2021 business EPS(2) to grow around 14% at CER(3), barring unforeseen major adverse events. Applying average October 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between -3.5% to -4.5% Sanofi Chief Executive Officer, Paul Hudson, commented: “Sanofi has delivered outstanding financial results in the third quarter. Double-digit sales growth in the period was driven by the remarkable performance of Dupixent®, record sales of Vaccines and business momentum in Consumer Healthcare, all in line with our strategic priorities. As a result of our sales performance and strong earnings, we have upgraded our full-year EPS guidance growth to around 14% at CER. In R&D, our growing pipeline of potentially transformative therapies has progressed, including the most recent positive readouts for Dupixent® in Eosinophilic esophagitis and Prurigo nodularis as well as the U.S. approval and launch of Nexviazyme® in Pompe disease. With higher R&D investment behind our pipeline assets and the two targeted bolt-on acquisitions of Translate Bio and Kadmon, we have further increased our commitment to bring innovative medicines to patients and drive future growth. Aligned with our contract with society and leading up to COP 26, we have set ourselves new ambitious ESG targets to reduce carbon emissions and accelerate our actions in fighting global climate change.” Q3 2021 Change Change at CER 9M 2021 Change Change at CER IFRS net sales reported €10,432m +10.1% +10.1% €27,767m +4.2% +8.2% IFRS net income reported(4) €2,317m +18.7% _ €5,093m -54.7% — IFRS EPS reported €1.85 +19.4% _ €4.07 -54.6% — Free cash flow(5) €2,202m +16.9% _ €5,555m +1.9% — Business operating income €3,558m +17.5% +17,3% €8,461m +9.7% +15.0% Business net income(2) €2,736m +19.0% +18.8% €6,484m +11.4% +16.9% Business EPS(2) €2.18 +19.1% +19.1% €5.18 +11.6% +17.2% Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 7) (1) Sanofi already raised its full-year 2021 business EPS growth guidance to around 12% at CER on July 29; (2) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 7). The consolidated income statement for Q3 2021 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (3) 2020 restated business EPS was €5.86; (4) 9M 2021 IFRS net income reported reflected capital gain from sales of Regeneron shares in Q2 2020; (5) Free cash flow is a non-GAAP financial measure (definition in Appendix 7) 2021 third-quarter and first nine months Sanofi sales ---------------------------- Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER1 ---------------------------- In the third quarter of 2021, Sanofi sales were €10,432 million, up 10.1% on a reported basis. Exchange rate movements had a neutral effect, the negative impact of the U.S. dollar, Japanese yen and Turkish lira was offset by the increase of the Chinese Yuan and some other currencies. In the first nine months Sanofi sales reached €27,767 million, up 4.2% on a reported basis. Exchange rate movements had a negative effect of 4.0 percentage points. At CER, company sales were up 8.2%. Global Business Units Third-quarter 2021 operating income Third-quarter business operating income (BOI) increased 17.5% to €3,558 million. At CER, BOI increased 17.3%. The ratio of BOI to net sales increased 2.2 percentage points to 34.1% (34.0% at CER). In the first nine months, BOI increased 9.7% to €8,461 million. At CER, BOI increased 15.0%. The ratio of business operating income to net sales increased 1.6 percentage points to 30.5% (30.8% at CER). Pharmaceuticals Third-quarter 2021 Pharmaceutical sales increased 7.8% to €6,855 million, mainly driven by the Specialty Care portfolio (up 20.2%) with continued strong performance of Dupixent® while sales in General Medicines decreased 1.7%. In the first nine months, Pharmaceuticals sales increased 7.7% to €20,051 million reflecting the strong performance of Specialty Care and General Medicines core assets. Specialty Care Dupixent Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Total Dupixent® 1,410 +54.6 % 3,700 +52.5 % In the third quarter, Dupixent® (collaboration with Regeneron) sales increased 54.6% to €1,410 million. In the U.S., Dupixent® sales of €1,061 million (up 47.7%) were driven by continued strong demand in atopic dermatitis (AD) in adults, adolescents, and children aged 6 to 11 years, and continued uptake in asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent® total prescriptions (TRx) increased 45% (year-over-year) and new-to-brand prescriptions (NBRx) grew 23% despite fewer in-person physician visits, which remain slightly below the pre-COVID level. In Europe, third-quarter Dupixent® sales grew 78.4% to €173 million reflecting continued growth in AD in key countries and additional launches in asthma in European markets. In Japan, sales were €78 million (up 68.8%). In the first nine months, Dupixent® sales reached €3,700 million, up 52.5%. Neurology and Immunology Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Aubagio® 483 -3.8 % 1,477 -1.7 % Lemtrada® 20 -16.7 % 63 -27.2 % Kevzara® 83 +42.4 % 196 +15.3 % Total Neurology and Immunology 586 +0.3 % 1,736 -1.4 % In the third quarter, Neurology and Immunology sales remained stable to €586 million, reflecting strong Kevzara® sales which were offset by lower Aubagio® sales. In the first nine months, Neurology and Immunology sales were down 1.4% reflecting decreased sales of Lemtrada® and Aubagio. Aubagio® sales decreased 3.8% in the third quarter to €483 million due to lower sales in the U.S. reflecting increased competition which was partially offset by higher sales in Europe and the Rest of the World. Third-quarter Kevzara® (collaboration with Regeneron) sales increased 42.4% to €83 million due to an increase in global demand for IL-6 receptor blockers and the temporary tocilizumab shortage. Rare Disease Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Myozyme® / Lumizyme® 266 +10.4 % 749 +8.4 % Fabrazyme® 209 +3.4 % 621 +5.7 % Cerezyme® 159 +0.6 % 502 +1.1 % Aldurazyme® 57 +5.5 % 180 +7.3 % Cerdelga® 64 +5.0 % 187 +10.9 % Others Rare Disease 24 +4.3 % 69 +10.8 % Total Rare Disease 779 +5.4 % 2,308 +6.1 % In the third quarter, Rare Disease sales increased 5.4% to €779 million driven by Pompe franchise performance. In the first nine months, sales of Rare Disease increased 6.1% reflecting growth across all three geographic regions. Third-quarter Myozyme®/Lumizyme® sales increased 10.4% to €266 million supported primarily by new patient accruals across geographic regions. Third-quarter Fabrazyme® sales increased 3.4% to €209 million driven by higher demand in Europe and the Rest of the World region, reflecting new patient accruals and improved treatment compliance. Sales of the Gaucher franchise (Cerezyme® + Cerdelga®) increased 1.8% (to €223 million) in the third quarter. Over the period, Cerezyme® sales increased 0.6% to €159 million, reflecting growth in the U.S. and Rest of World region. In Europe Cerezyme® sales were down 4.8% as Cerdelga® sales were up 5.0% globally driven by new patient accruals in Europe. Oncology Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Jevtana® 105 -20.9 % 345 -10.9 % Sarclisa® 48 +276.9 % 122 +605.6 % Fasturtec® 37 -9.5 % 111 +1.8 % Libtayo® 35 +61.9 % 94 +95.8 % Total Oncology 225 +8.1 % 672 +19.3 % Third-quarter and first-nine months sales of Oncology increased 8.1% (to €225 million) and 19.3%, respectively, driven by the Sarclisa® and Libtayo® launches which more than offset the impact of Jevtana® generic competition in Europe. Third-quarter Jevtana® sales decreased 20.9% to €105 million following the entry of generic competition in certain European markets (down 58.3%) at the end of March. In the U.S., sales were up 1.6%, where the Jevtana® composition of matter patent has expired in September 2021. However, Sanofi has filed patent infringement suits against generic on Jevtana® under Hatch-Waxman in the U.S. District Court for the District of Delaware asserting three method of use patents, two of which (US 10,583,110 and US 10, 716,777) expire in October 2030 and the other one (US 8,927,592) expires in April 2031 including 6-month pediatric exclusivities. Sanofi has reached settlement agreements with some of the defendants and the suit against the remaining defendants is ongoing. No trial dates has been scheduled and the remaining defendants have agreed not to launch any generic cabazitaxel product until the earlier of a district court decision in favor of the defendants or four months after the completion of the post-trial briefing. Separately, Jevtana® has been granted a data exclusivity on the CARD clinical study results which expires in December 2023. Third-quarter Sarclisa® sales were €48 million (versus €13 million in the third quarter of 2020) driven by additional country launches in Europe (€17 million), higher sales in the U.S (€18 million) and in the Rest of the world region (€13 million) driven by the uptake in Japan. Libtayo® (collaboration with Regeneron) sales were €35 million (up 61.9%) in the third quarter driven by increased demand in metastatic cutaneous squamous cell carcinoma (CSCC) as well as additional country launches. Libtayo® sales in the U.S. are reported by Regeneron. Rare Blood Disorders Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Eloctate® 144 -4.6 % 422 -7.3 % Alprolix® 101 -6.4 % 301 -4.8 % Cablivi® 42 +32.3 % 126 +56.6 % Total Rare Blood Disorders 287 -1.4 % 849 -0.4 % In the third quarter, Rare Blood Disorders franchise sales decreased 1.4% (€287 million). Excluding industrial sales to Sobi, third-quarter sales were up 7.1% mainly driven by Cablivi®. Alprolix® and Eloctate® industrial sales to Sobi are expected to be significantly lower in 2021 than in 2020 due to a change in the supply agreement. In the first nine months sales of Rare Blood Disorders decreased 0.4% and were up 9.8.% when excluding industrial sales to Sobi. Eloctate® sales were €144 million in the third quarter, down 4.6%. Excluding industrial sales to Sobi, Eloctate sales were up 2.2% driven by higher U.S. sales (+3.7%) which benefited from buying patterns in the quarter . Sales in the Rest of the World were down 25.0% reflecting lower industrial sales to Sobi (which are recorded in this region). Third-quarter Alprolix® sales were down 6.4% to €101 million. Excluding industrial sales to Sobi, Alprolix® sales were up 6.3% driven by U.S. sales (up 5.0%) which benefited from buying patterns in the quarter. Sales in the Rest of the World were down 37.9% reflecting lower industrial sales to Sobi (which are recorded in this region). Cablivi® generated sales of €42 million (up 32.3%) in the third quarter driven by launches in Europe (up 120.0% to €22 million). In the U.S., sales of the product were €19 million, down 9.5% reflecting the impact of the COVID-19 environment on treatment initiations with Cablivi® at the hospital level. General Medicines Third quarter General Medicines sales decreased 1.7% to €3,568 million. The growth of core assets2 (up 4.5% to €1,437 million and up 5.6% excluding Praluent® U.S. sales) was more than offset by the non-core assets sales decrease (down 6.3% to €1,923 million) mainly reflecting lower Lantus® sales in the U.S., portfolio streamlining (-1.3 ppt impact) and a decline in Aprovel®/Avapro® sales. Third-quarter Industrial sales3 were €208 million up 2.5%. Excluding portfolio streamlining, third quarter General Medicines sales were down 0.7% (- 1.0 ppt impact). In the first nine months, General Medicines sales were down 0.6% to €10,786 million. During the same period, sales of the core assets were €4,339 million up 6.8%, driven by strong performance of Lovenox®, Toujeo® and Thymoglobulin®. Non-core assets sales were €5,859 million, down 5.8% reflecting portfolio streamlining (-2.0 ppt), as well as lower Lantus® and Aprovel®/Avapro® sales. Over the same period, Industrial sales were €588 million up 4.2%. Excluding portfolio streamlining, General Medicines sales were up 0.5 % (-1.1 ppt impact). Diabetes Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Lantus® 622 -5.9 % 1,911 -4.1 % Toujeo® 239 +11.1 % 739 +7.9 % Total glargine 861 -1.7 % 2,650 -1.0 % Soliqua® 51 +27.5 % 141 +28.7 % Other diabetes 211 -6.6 % 653 -3.7 % Total Diabetes 1,123 -1.7 % 3,444 -0.6 % In the third quarter, global Diabetes sales decreased 1.7% to €1,123 million. Sales growth in the Rest of the Word (up 9.3%) was more than offset by lower sales in the U.S. (down 13.4%) and Europe (down 3.2%). In the first nine months, Diabetes sales were down 0.6% mainly as a result of lower Lantus® sales partially offset by growth from Toujeo® and Soliqua®. Third-quarter Toujeo® sales increased 11.1% to €239 million reflecting growth across all geographies and strong growth in the Rest of World region (up 20.0%). Lantus® sales were €622 million, down 5.9% in the third quarter, reflecting lower sales in the U.S. and Europe due to a continued decline in average U.S. net price, increasing use of Toujeo® and biosimilar glargine competition. In the Rest of World region, Lantus® sales were up 10.1% driven by China. Third-quarter Soliqua® sales increased 27.5% to €51 million driven by growth in all three geographic regions. In the Rest of World region, third-quarter Soliqua® sales grew 40.0% mainly due to new launches. Cardiovascular and Established Rx Products Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Lovenox®* 383 +4.4 % 1,151 +19.1 % Plavix®* 222 +6.3 % 707 +1.0 % Aprovel®/Avapro® 107 -21.8 % 307 -29.4 % Thymoglobulin® 91 +4.6 % 263 +16.1 % Multaq® 79 0.0 % 230 +4.3 % Praluent® 59 +18.0 % 163 -15.8 % Mozobil® 60 +7.1 % 170 +13.5 % Generics 172 -10.9 % 566 -0.3 % Other 1,064 -4.0 % 3,197 -5.0 % Total Cardiovascular and Established Rx Products 2,237 -2.1 % 6,754 -1.0 % *Excluding Auto generics In the third quarter, Cardiovascular andEstablished Rx Products sales decreased 2.1% to €2,237 million. The performance of the core assets including Lovenox®, Plavix®, Thymoglobulin®, Mozobil® and Praluent® was more than offset by lower sales of Aprovel®/Avapro® and generics as well as the impact of the divestments of non-core products. In the first nine months, Cardiovascular and Established Rx Products sales were down 1.0% (up 0.1% excluding Praluent® U.S. sales) mainly due to lower Aprovel®/Avapro® sales and the divestments which offset strong growth of several core assets. Third-quarter Lovenox® sales increased 4.4% to €383 million, driven by strong sales in Rest of World region (up 9.5%). COVID-19 related demand continued to be strong (guidelines recommending the use of low molecular weight heparins in hospitalized COVID-19 patients). However, growth performance was impacted by a comparable high base in the third quarter of 2020, supply limitations and biosimilar competition in Europe (down 1.8%). Plavix® sales were up 6.3% in the third quarter to €222 million due to higher sales in Rest of World (up 9.2%) driven by China (up 16.7% to €90 million) largely offsetting lower sales in Japan and Europe. Third-quarter Aprovel®/Avapro® sales were down 21.8% to €107 million reflecting supply constraints. Third-quarter Praluent® sales increased 18.0% to €59 million, reflecting the restructuring of the collaboration with Regeneron effective April 1, 2020. Sanofi has sole responsibility for Praluent® outside the U.S. while Regeneron has sole responsibility for Praluent® in the U.S. Excluding U.S. sales in the comparable quarter last year, higher Praluent® sales (up 63.9%) were driven by the launch in China and strong performance in Europe. Multaq® third quarter sales were stable at €79 million, reflecting U.S. sales growth which was offset by lower sales in Europe. Pharmaceuticals business operating income In the third quarter, business operating income (BOI) of Pharmaceuticals increased 2.8% to €2,409 million (up 1.7% at CER). The ratio of BOI to net sales decreased by 1.7 percentage points to 35.1%. At CER, the ratio decreased 2.0 percentage points reflecting Regeneron MAbs alliance and increased R&D expenses in priority assets and commercial expenses in Specialty Care growth drivers, despite an improvement of the gross margin ratio. In the first nine months, business operating income of Pharmaceuticals decreased 1.2% to €7,320 million (up 3.1% at CER). The ratio of BOI to net sales decreased by 1.7 percentage points to 36.5% (36.6% at CER). Vaccines Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Polio/Pertussis/Hib vaccines (incl. Hexaxim® / Hexyon®, Pentacel®, Pentaxim® and Imovax®) 563 +1.8 % 1,616 +3.1 % Influenza vaccines (incl. Vaxigrip®, Fluzone HD®, Fluzone® & Flublok®) 1,339 +25.5 % 1,535 +23.9 % Meningitis/Pneumo vaccines (incl. Menactra®) 253 +18.7 % 567 +36.2 % Adult Booster vaccines (incl. Adacel®) 158 +4.6 % 364 +8.7 % Travel and other endemic vaccines 82 +16.9 % 215 -1.3 % Other vaccines 27 +8.7 % 62 +18.5 % Total Vaccines 2,422 +16.5 % 4,359 +13.8 % Third-quarter Vaccines sales grew 16.5% to €2,422 million driven by influenza vaccines performance and meningitis vaccination recovery in the U.S. In the first nine months, Vaccines sales grew 13.8% due to the strong performance of the influenza vaccines franchise and a recovery of meningitis vaccines more than offsetting the negative COVID-19 impact on the travel vaccines. In the third quarter, Polio/Pertussis/Hib (PPH) vaccines sales increased 1.8% to €563 million. In Europe, PPH sales decreased 11.2% reflecting unfavorable phasing effect and lower birth rates due to the pandemic. In Rest of World, PPH sales were up 3.5% supported by Pentaxim® in China and Polio vaccines which largely offset the impact of lower birth rates. In the U.S., PPH sales increased 6.8% due to positive inventory fluctuation. VaxelisTM, the first and only hexavalent combination vaccine approved in the U.S., was launched in the U.S. in June 2021. Developed as part of a joint-partnership between Sanofi and Merck, VaxelisTM in-market sales are not consolidated and the profits shared equally between the two parties. As Vaxelis™ is expected to partly replace Pentacel® sales, PPH sales in the U.S. are expected to decrease going forward. Influenza vaccines sales increased 25.5% in the third quarter to €1,339 million as a result of earlier shipments in the U.S and a strong increase in differentiated influenza vaccines in Europe driven by Germany which adopted a preferential recommendation for Efluelda® for people above 60 years old. Influenza vaccines sales in the U.S and in Europe grew 18.1% (to €982 million) and 87.8% (to €247 million), respectively. Third-quarter Meningitis sales were up 18.7% to €253 million mainly with the recovery of meningitis vaccination in the U.S. and in Middle East in conjunction with the U.S. launch of MenQuadfi® in March 2021. Adult Booster vaccines sales grew 4.6% in the third quarter to €158 million, due to the gradual recovery of Adacel® vaccinations in the U.S. Third-quarter Travel and other endemic vaccines sales increased 16.9% versus a low 2020 basis. Vaccines business operating income In the third quarter, business operating income (BOI) increased 29.8% to €1,359 million reflecting the strong sales growth. At CER, BOI increased 29.5%. The ratio of BOI to net sales was 56.1% (versus 50.4% in the third quarter of 2020) reflecting a favorable product mix driven by influenza vaccines and Meningitis vaccines as well as good industrial performance. In the first nine months, BOI increased 30.7% (up 33.0% at CER) to €1,957 million reflecting strong sales performance as well as the payment from Daiichi Sankyo in the first quarter of 2021. The ratio of BOI to net sales increased 6.6 percentage points to 44.9% (44.7% at CER). Consumer Healthcare Net sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER Allergy 142 +17.4 % 485 +2.2 % Cough, Cold and Flu 94 +4.4 % 204 -30.9 % Pain Care 290 +18.2 % 818 +7.3 % Digestive Wellness 282 +16.0 % 855 +21.8 % Physical Wellness 85 -7.7 % 244 -5.7 % Mental Wellness 53 +8.2 % 160 +16.8 % Personal Care 135 +5.4 % 387 +2.8 % Non-Core / Others 74 +4.2 % 204 -5.8 % Total Consumer Healthcare 1,155 +11.1 % 3,357 +4.2 % In the third quarter, Consumer Healthcare (CHC) sales increased 11.1% to €1,155 million driven by growth in all three geographic regions and the performance of the Digestive Wellness category, as well as the Pain Care category which also benefited from COVID-19 vaccinations. In the first nine months CHC sales increased 4.2% mainly due to the growing sales in Digestive Wellness, Pain Care and Mental Wellness categories which more than offset a weak cough and cold season last winter and the divestments of non-core products (-0.6 ppt impact). In the U.S., third-quarter CHC sales increased 16.4% to €289 million driven by strong growth of Pain Care, Personal Care (driven by Gold bond) and Digestive Wellness categories as well as Allergy which benefited from a low base for comparison. In Europe, third-quarter CHC sales increased 3.1% to €335 million mainly reflecting growth of Pain Care and Digestive categories which more than offset lower sales from the Cough, Cold and Flu category due to the impact of social distancing measures. In Rest of World, third-quarter CHC sales increased 13.9% to €531 million, supported by strong growth of Pain Care and Digestive Wellness categories as well as higher sales from the Allergy category. CHC business operating income In the third quarter, business operating income (BOI) of CHC increased 44.1% (44.4% at CER) to €464 million reflecting higher sales and a strict control of operational expenses. The ratio of BOI to net sales increased 9.3 percentage point to 40.2% versus the prior year and included a €77 million capital gain related to divestment of non-strategic assets. In the first nine months of 2021, BOI of CHC increased 8.0% (up 14.5% at CER) to €1,195 million. The ratio of BOI to net sales increased 2.7 percentage points to 35.6% (36.1% at CER). Company sales by geographic region Sanofi sales (€ million) Q3 2021 Change at CER 9M 2021 Change at CER United States 4,477 +13.4 % 10,565 +13.4 % Europe 2,483 +8.9 % 6,955 +5.3 % Rest of the World 3,472 +6.7 % 10,247 +5.0 % of which China 782 +12.8 % 2,162 +8.5 % of which Japan 423 +13.3 % 1,253 +2.1 % of which Brazil 198 +14.8 % 651 +16.7 % of which Russia 139 -0.7 % 439 -3.8 % Total Sanofi sales 10,432 +10.1 % 27,767 +8.2 % Third-quarter sales in the U.S. increased 13.4% to €4,477 million supported by the strong performance of Dupixent® and double-digit growth of Vaccines and CHC. In the first nine months, U.S. sales grew 13.4%, mainly reflecting Dupixent® and Vaccines performance. In Europe sales increased 8.9% in the third quarter to €2,483 million mainly driven by strong Vaccines growth and Dupixent® performance. In the first nine months, European sales increased 5.3% due to the growth of Specialty Care products driven by Dupixent® and Vaccines which more than offset lower sales of General Medicines and CHC. In Rest of World sales increased 6.7% to €3,472 million in the third quarter, driven by the performance of Dupixent®, General medicine and CHC. Sales in China increased 12.8% to €782 million mainly sustained by Dupixent®, Vaccines, CHC and General Medicines performance. In Japan, third-quarter sales increased 13.3% to €423 million reflecting the strong performance of Dupixent® and Sarclisa®. In Rest of World first-nine months sales increased 5.0% mainly supported by growth of Dupixent®, Oncology, General Medicines and CHC. R&D update at the end of the third quarter 2021 Regulatory update The U.S. Food and Drug Administration (FDA) approvedNexviazyme® (avalglucosidase alfa) for the treatment of patients one year of age and older with late-onset Pompe disease. Nexviazyme® was also approved in Japan. Nexviazyme® is a long-term enzyme replacement therapy targeting the mannose-6-phosphate receptor, the key pathway for cellular uptake of enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells. The approval was based on the Phase 3 COMET study, showing clinically meaningful improvements in respiratory function and movement endurance measures in people with late-onset Pompe disease. The European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Nexviazyme® (avalglucosidase alfa), for the treatment of Pompe disease. However, they considered that avalglucosidase alfa does not qualify as a New Active Substance (NAS), leading Sanofi to be requesting a re-examination of the CHMP opinion in relation to the NAS conclusion. The FDA accepted the resubmission of the Biologics License Application (BLA) for sutimlimab, its investigational therapy for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). The FDA is reviewing the BLA under priority review with a PDUFA action date of February 5, 2022. Sutimlimab has previously received Breakthrough Therapy Designation (BTD) and Orphan Drug Designations (ODD) from the FDA. Olipudase alfa, an investigational recombinant human acid sphingomyelinase for the treatment of Acid Sphingomyelinase Deficiency (ASMD), was submitted in Japan on September 30th, through the Sakigake regulatory pathway. The FDA accepted for priority review of the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo® (cemiplimab) to treat patients in 2L with recurrent or metastatic cervical cancer. The FDA approvedfexinidazole, the first 10-day once-a-day oral treatment for Trypanosoma brucei gambiensesleeping sickness, in patients 6 years of age and older and weighing at least 20 kg. Both first stage and second stage of the disease are targeted, in which the parasites have crossed the blood-brain barrier, causing patients to suffer from neuropsychiatric symptoms. The China National Medical Products Administrations (NMPA) approved the use of Dupixent® (dupilumab), for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The FDA granted Fast-Track Designation for SAR443820, a RIPK1 inhibitor currently in Phase 1, for the amyotrophic lateral sclerosis (ALS) indication. The FDA granted ODD for SAR445088 (formerly known as BIVV020), a complement C1s inhibitor currently in Phase 2, for the treatment of Chronic inflammatory demyelinating polyneuropathy (CIDP). Portfolio update Phase 3: Dupixent®met its primary and all key secondary endpoints in Study A (the first of two trials) of the pivotal LIBERTY CUPID clinical program, showing a nearly doubled reduction in itch and urticaria activity scores, compared to antihistamines (standard-of-care treatment), in patients with moderate-to-severe chronic spontaneous urticaria (CSU). Study B of the clinical trial evaluates Dupixent® in adults and adolescents who remain symptomatic despite standard-of-care treatment and are intolerant or incomplete responders to an anti-IgE therapeutic (omalizumab). This study is expected to read out in H1 2022. CSU is an inflammatory skin disease, affecting more than 300,000 patients in the U.S. alone. The pivotal trial evaluating Dupixent® (dupilumab) for the treatment of children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, met its primary and all secondary endpoints. The data show adding Dupixent® to standard of care topical corticosteroids (TCS) significantly reduced the overall disease severity and improved the skin clearance, itch and health-related quality of life measures at 16 weeks compared to TCS alone. Detailed data from the MELODY study for nirsevimab to prevent respiratory illness caused by RSV (Respiratory Syncytial Virus) in infants was presented at the IDWeek congress showing a 74.5% reduction in medically attended LRTI (Lower Respiratory Tract Infections) after 5 months of follow up. The study evaluating Libtayo® in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival primary endpoint, compared to chemotherapy alone, in first-line treatment of patients with advanced non-smallcell lung cancer(NSCLC), with metastatic or locally advanced disease and tumors with either squamous or non-squamous histology and across all PD-L1 expression levels. Results were presented at the 2021 European Society of Oncology (ESMO) congress. The PEGASUS phase 3 trial, evaluating rilzabrutinib, a BTK inhibitor for the treatment of pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints. The proportion of patients meeting the primary endpoint on Rilzabrutinib, was not significantly different from placebo. Rilzabrutinib continues to be investigated in a Phase 3 trial for the treatment of immune thrombocytopenia, a rare blood disorder, and in a Phase 2 study for the autoimmune condition IgG4-related disease. Additional Phase 2 studies in immunological and rare blood disorders diseases including asthma, atopic dermatitis, chronic spontaneous urticaria and warm autoimmune hemolytic anemia are planned to start in 2021. A potential filing date for fitusiran, a small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors, has been moved to 2024 due the introduction of a lower dose cohort in the ongoing phase 3 studies. The lower dose may be available to those patients currently on 50 mg every other month with anti-thrombin levels below the lower threshold of 15% and may enable them to continue to receive prophylactic treatment with fitusiran. A new phase 3 study evaluating the safety pro Nexviazyme® in infantile-onset Pompe Disease was initiated in children from 6 months to 17 years. Patient enrollment is ongoing in EU and ROW in the phase 3 multicenter, open-label ELIKIDS study of Cerdelga® in pediatric patients with Gaucher Disease Type 1 and Type 3, under the pediatric investigation plan (PIP) as part of the overall clinical development plan. Submission is currently planned for 2025. Given the integral nature of the project it is not detailed anymore on the overall Sanofi pipeline chart. MenQuadfi®, a quadrivalent ACWY vaccine, met all primary and secondary endpoints, demonstrating the induced superior immune responses to serogroup C based on geometric mean antibody titers (GMTs) compared to NeisVac-C (monovalent C vaccine) - standard-of-care vaccine- , in healthy toddlers. The data also showed superior immune responses to serogroup C based on seroprotection rates and GMTs compared to Nimenrix® (quadrivalent ACWY vaccine) in this population. MenQuadfi is approved in Europe for use as a single dose in individuals 12 months of age and older for the prevention of invasive meningococcal ACWY disease. In the US it is licensed for the prevention of invasive meningococcal disease in individuals 2 years of age and older. Phase 2 Positive results from a Phase 2a study evaluating the safety and efficacy of amlitelimab in patients with moderate-to-severe atopic dermatitis, were presented as a late-breaker at the European Academy of Dermatology and Venerology (EADV) 2021 Virtual Congress. Amlitelimab, formerly known as KY1005, is a human monoclonal antibody targeting immune system regulator OX40-Ligand At week 16, the data demonstrated that when dosed intravenously every four weeks an 80% improvement in average EASI from baseline for the low dose and a 70% improvement in average EASI from baseline for the high dose was achieved, compared to 49% for the placebo group indicating a consistent pharmacological effect of blocking OX40-L. A Phase 2b dose ranging study is about to start, including lower doses and subcutaneous injection. SAR444727 (formerly known as PRN473), a topically administered BTK inhibitor, entered Phase 2a study, evaluating safety, tolerability, and pharmacokinetics in patients with mild-to-moderate atopic dermatitis. Data of tolebrutinib, an oral brain penetrant BTK inhibitor, were published in Lancet Neurology. The Phase 2b trial showed both safety and efficacy in relapsing multiple sclerosis. The treatment led to a dose-dependent reduction in new gadolinium-enhancing lesions, leading to a reduction of acute inflammation, while the drug was well tolerated. The phase 3 clinical trials in patients with relapsing and progressive forms of multiple sclerosis are currently enrolling. SAR444245 (formerly known as THOR707), a novel non-alpha IL-2, entered a phase 2 basket trial in combination with Libtayo® for the treatment of various advanced skin cancers. A phase 2 study cohort evaluating safety and efficacy of Sarclisa® in combination with atezolizumab in 1L mCRC was terminated. A phase 2 study evaluating the safety and efficacy of Sarclisa®, in Adults with Warm Autoimmune Hemolytic Anemia (wAIHA) was initiated. The phase 1/2 study of SP0254, an mRNA-based COVID-19 vaccine candidate, delivered positive interim results confirming the company’s platform robust capabilities and strategy in mRNA. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going forward, the development of SP0254 will not be further continued. Phase 1 SAR443216, an anti-CD3xCD28xHER2 trispecific antibody, entered phase 1 study for the treatment of metastatic gastric cancers with HER2 low expression or HER2 mutation. SAR443726, a novel IL13/OX40L nanobody entered a first-in-human, three-part, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants and in adult participants with moderate-to-severeatopic dermatitis. Sangamo and Sanofi are continuing to advance the zinc finger genome editing program (SAR445136, formerly known as BIVV003) for sickle cell disease. The companies recently obtained manufacturing requirements guidance from FDA in preparation for further clinical studies and expect to share preliminary data from the sickle cell program at an upcoming meeting. The parties agreed to terminate the program addressing transfusion-dependent β-thalassemia (ST400) while focusing resources on the sickle cell disease indication. Acquisitions On September 14, Sanofi completed the acquisition of Translate Bio, acquiring all of their outstanding shares for $38.00 per share in cash, representing a total equity value of approximately $3.2 billion. Translate Bio is a clinical-stage mRNA therapeutics company, having already signed a collaboration with Sanofi in 2018, to develop mRNA vaccines which was further expanded in 2020 to broadly address current and future infectious diseases. The acquisition builds on Sanofi’s establishment of a first-of-its kind vaccines mRNA Center of Excellence. On September 8, Sanofi entered into a definitive agreement to acquire Kadmon Holdings4 for $9.50 per share in cash, which represents a total equity value of approximately $1.9 billion. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock™(belumosudil) to its transplant portfolio. This latter, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, has been recently FDA-approved, first-in-class treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy. An update of the R&D pipeline as of September 30, 2021, is available on our website. Progress on implementation of the Corporate Social Responsibility strategy Sanofi is accelerating its efforts to address climate change and intends to achieve net zero5 greenhouse gas (GHG) emissions across all operations (scope 1 & 2) and the entire value chain (scope 3) by 2050. In alignment with the 1.5°C pathway, this new commitment will be building on years of work to reduce the environmental footprint of its products and activities through its Planet Mobilization program. In this journey, the company has also set an interim target to reach by 2030 carbon neutrality6 across all scopes of emissions, 20 years ahead of its previous commitment made in 2015 after the COP21 and the Paris Agreement. Sanofi’s carbon footprint (scope 1 and 2) has decreased by –27% between 2015 and 2020. As per today, renewable electricity represents 50% of total electricity consumption, on track to reach 100% of renewable electricity supply in 2030, and its RE1007 commitment. As a result of an eco-driving policy and the renewal of the car fleet, the eco fleet represents 22% of total car fleet today with the objective to reach 100% by 2030. The company will continue to report on progress annually to ensure its efforts are on track. Finally, in the run-up to the 26th UN Climate Change Conference of the Parties (COP26), Sanofi has joined the UN’s 'Race to Zero' initiative. This global campaign mobilizes cities, regions, investors and 20% of the major companies by revenue committing to net zero carbon emissions by 2050. The COP26 will take place in Glasgow (UK) from October 31 until November 12, 2021. In recognition of Sanofi’ ESG strategy implementation, Sanofi is ranked #1 in the European pharmaceutical sector in the latest international ESG ranking issued by Vigeo Eiris (V.E), published late August 2021. V.E, which is part of Moody’s ESG Solutions, is an independent international ESG rating agency. Its assessment is based on information covering 28 areas of interest ranging from climate change, health, safety, and environmental issues to human and labor rights. VE's ESG scores measure the degree to which companies factor and manage material Environmental, Social and Governance factors. Across the pharmaceutical sector globally, Sanofi scored of 62/100 points moving up from its fourth place in the ranking one year ago. Embedded in Sanofi's long-term Play to Win strategy, the company’s ESG strategy is based on four essential pillars. Sanofi Global Health, a newly formed nonprofit unit within the company, will provide thirty of Sanofi's medicines across a wide range of therapeutic areas to patients in 40 of the lowest income countries. Sanofi Global Health will also fund the training of healthcare professionals and the development of sustainable care systems. Sanofi continues its efforts to fight polio and sleeping sickness, two of its historical programs that address global health issues. Sanofi is the only pharmaceutical company that keeps developing and supplying treatments for sleeping sickness. It has committed itself alongside the WHO to eliminate this neglected tropical disease in humans by 2030. Over the years, Sanofi has supplied billions of polio vaccine doses, including hundreds of millions of donated doses to support the global polio eradication effort. To contribute to better resource conservation, Sanofi plans to remove all pre-formed plastic packaging (blister packs) for its vaccines by 2027. In addition, the company is committed to ecodesigning all its new products by 2025. To reduce its greenhouse gas emissions by 55% by 2030, all Sanofi sites will use 100% renewable electricity and the company has set a target of a carbon-neutral car fleet, both by 2030. As a global company, Sanofi is committed to ensuring that its leaders reflect the communities and patients it serves. The company is committed to continue fostering an organization where all employees have equal opportunities to reach positions of responsibility within the company. Sanofi also keeps its commitment to making a strong contribution to current global public health priorities, with the supply of half a billion doses of authorized vaccines. Sanofi is the only company leveraging its worldwide manufacturing capacity and expertise for the supply of three different authorized COVID-19 vaccines from BioNTech / Pfizer, Moderna, and Johnson & Johnson. Manufacturing teams on three industrial sites of the company in France, Germany and the U.S. are mobilized, with 30 million doses released by end September. At the same time, Sanofi continues its efforts in the fight against the COVID-19 pandemic with its adjuvanted recombinant protein candidate vaccine, developed in partnership with GSK. In parallel to its ongoing Phase 3 efficacy and safety study, Sanofi has expanded its development program to include a study of the vaccine as a potentially broadly protective booster to address evolving public health needs. First data readout is expected before year-end. 2021 third-quarter and the first nine months financial results Business Net Income8 In the third quarter of 2021, Sanofi generated net sales of €10,432 million, an increase of 10.1% (on a reported basis and at CER). In the first nine months, net sales were €27,767 million up 4.2% (up 8.2% at CER). Third-quarter other revenues decreased 0.7% (up 0.2% at CER) to €397 million, reflecting decreased VaxServe sales of non-Sanofi products (€336 million, down 5.3% at CER). In the first nine months, other revenues increased 2.0% (up 8.1% at CER) to €993 million, including higher VaxServe sales of non-Sanofi products (€790 million, up 0.8% at CER). Third-quarter Gross Profit increased 13.0% (on a reported basis and at CER) to €7,591 million. The gross margin ratio increased 1.9 percentage points to 72.8% versus the third quarter of 2020. This improvement mainly reflected efficiency gains in Industrial Affairs, favorable impact of growing weight of Specialty Care (the Pharmaceuticals gross margin ratio improved from 73.5% to 75.2%), positive product mix of Vaccines (Vaccines gross margin ratio increased 3.7 percentage point to 72.0% which more than offset lower CHC gross margin ratio (64.7% versus 66.6%). In the first nine months, the gross margin ratio increased 0.9 percentage point to 72.0% (72.1% at CER). Research and Development (R&D) expenses increased 9.2% (up 9.3% at CER) to €1,443 million in the third quarter, reflecting increase in priority assets development and early pipeline as well as recent acquisitions partly offset by efficiencies. In the first nine months, R&D expenses increased 2.3% to €4,106 million and were up 4.9% at CER as increased investment behind key assets were partly offset by the benefits of terminating diabetes and cardiovascular care related projects recorded in 2020. Third-quarter selling general and administrative expenses (SG&A) increased 3.9% to €2,267 million. At CER, SG&A expenses were up 3.6%, reflecting increased commercial investments in Specialty Care growth drivers which were partially offset by continued streamlining of General and Administrative expenses (G&A). In the third quarter, the ratio of SG&A to sales decreased 1.3 percentage points to 21.7% compared to the prior year. In the first nine months, SG&A expenses increased 0.1% to €6,797 million (up 3.6% at CER). In the first nine months, ratio of SG&A to sales was 1.0 percentage point lower at 24.5% compared to the prior year. Third-quarter operating expenses were €3,710 million, an increase of 5.9% and 5.7% at CER. In the first nine months operating expenses were €10,903 million, an increase of 0.9% and an increase of 4.1% at CER. Third-quarter other current operating income net of expenses was -€289 million versus -€182 million in the third quarter of 2020. Other current operating income net of expenses included an expense of €399 million (versus an expense of €229 million in the third quarter of 2020) corresponding to the share of profit to Regeneron of the monoclonal antibodies Alliance, reimbursement of development costs by Regeneron and the reimbursement of commercialization-related expenses incurred by Regeneron. In the first nine months, other current operating income net of expenses was -€589 million versus -€437 million in the same period of 2020. The share of profit from associates was -€5 million versus €1 million in Q3 2020 and included the share of U.S profit related to VaxelisTM. Third-quarter business operating income8 (BOI) increased 17.5% to €3,558 million. At CER, BOI increased 17.3%. The ratio of BOI to net sales was 34.1% versus 31.9% in Q3 2020 reflecting seasonal contribution of flu vaccines, gross margin ratio improvement as well as SG&A ratio improvement. In the first nine months, business operating income was €8,461 million, up 9.7% (up 15.0% at CER) and the ratio of business operating income to net sales increased 1.6 percentage points to 30.5% (30.8% at CER). Net financial expenses were €85 million in the third quarter versus €76 million in the same period of 2020. Third-quarter and the first-nine months 2021 effective tax rate was 21.0% versus 22% in the prior year. Sanofi expects its effective tax rate to be around 21% in 2021, everything being equal in the U.S. Third-quarter business net income8 increased 19.0% to €2,736 million and increased 18.8% at CER. The ratio of business net income to net sales increased 1.9 percentages points to 26.2% versus the third quarter of 2020. In the first nine months, business net income increased 11.4% to €6,484 million and increased 16.9% at CER. The ratio of business net income to net sales increased 1.6 percentage points to 23.4% versus the same period of 2020. In the third quarter of 2021, business earnings per share8 (EPS) was €2.18, up 19.1% on a reported basis (and at CER). The average number of shares outstanding was 1,254.5 million versus 1,255.7 million in third quarter 2020. In the first nine months of 2021, business earnings per share8 was €5.18, up 11.6% on a reported basis and up 17.2% at CER. The average number of shares outstanding was 1,251.7 million in the first nine months of 2021 versus 1,253.0 million in the first nine months 2020. Reconciliation of IFRS net income reported to business net income (see Appendix 4) In the first nine months of 2021, the IFRS net income was €5,093 million. The main items excluded from the business net income were: An amortization charge of €1,160 million related to fair value remeasurement on intangible assets of acquired companies (primarily Genzyme: €380 million, Bioverativ: €238 million, Boehringer Ingelheim CHC business: €148 million and Ablynx: €126 million) and to acquired intangible assets (licenses/products: €70 million). These items have no cash impact on the Company. An impairment of intangible assets of €177 million mainly related to sutimlimab (termination of ITP). Restructuring costs and similar items of €494 million related to streamlining initiatives. A €440 million tax effect arising from the items listed above, mainly comprising €320 million of deferred taxes generated by amortization and impairments of intangible assets and €121 million associated with restructuring costs and similar items (see Appendix 4). Capital Allocation In the first nine months of 2021, free cash flow before restructuring, acquisitions and disposals increased by 21.0% to €6,968 million, after net changes in working capital (+€218 million) and capital expenditures (-€953 million). After acquisitions9 (-€1,093 million of which Kiadis -€319 million, Tidal Therapeutics -€135 millions), proceeds from disposals9 (+€461 million), and payments related to restructuring and similar items (-€781 million), free cash flow10 increased 1.9% to €5,555 million, reflecting recent acquisitions to strengthen the long-term pipeline and less proceeds compared to last year as Seprafilm was divested in Q1 2020 (€311 million). After the acquisition of Translate Bio (-€ 2,397 million) and Kymab (-€922 million) and the dividend paid by Sanofi (-€4,008 million), net debt increased from €8,790 million at December 31, 2020 to €10,427 million at September 30, 2021 (amount net of €9,785 million cash and cash equivalents). Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Sanofi’s ability to complete the proposed transaction with Kadmon Holdings, Inc. on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing business combination transactions, as well as other risks related to Sanofi’s business, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Appendices List of appendices Appendix 1: 2021 third-quarter and first nine months sales by GBU, franchise, geographic region and product Appendix 2: 2021 third-quarter and first nine months business net income statement Appendix 3: 2021 third-quarter and first nine months consolidated income statement Appendix 4: Reconciliation of IFRS net income reported to business net income Appendix 5: Change in net debt Appendix 6: Currency sensitivity Appendix 7: Definitions of non-GAAP financial indicators Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - Media Relations: (+) 33 1 53 77 46 46 - E-mail: MR@sanofi.com Website: Appendix 1: 2021 third-quarter net sales by GBU, franchise, geographic region and product Q3 2021 (€ million) Total Sales % CER % reported United States % CER Europe % CER Rest of the world % CER Dupixent 1,410 54.6 % 53.6 % 1,061 47.7 % 173 78.4 % 176 82.3 % Aubagio 483 -3.8 % -4.4 % 328 -6.8 % 122 1.7 % 33 10.0 % Lemtrada 20 -16.7 % -16.7 % 9 -35.7 % 7 -14.3 % 4 66.7 % Kevzara 83 42.4 % 40.7 % 49 75.0 % 24 33.3 % 10 -15.4 % Neurology & Immunology 586 0.3 % -0.3 % 386 -2.0 % 153 4.8 % 47 6.5 % Cerezyme 159 0.6 % -1.9 % 45 4.7 % 59 -4.8 % 55 3.5 % Cerdelga 64 5.0 % 6.7 % 33 0.0 % 26 13.0 % 5 0.0 % Myozyme 266 10.4 % 10.4 % 103 13.2 % 105 6.1 % 58 13.5 % Fabrazyme 209 3.4 % 2.5 % 101 0.0 % 53 3.9 % 55 9.8 % Aldurazyme 57 5.5 % 3.6 % 13 7.7 % 20 0.0 % 24 9.1 % Rare Disease 779 5.4 % 4.6 % 296 5.7 % 264 3.5 % 219 7.2 % Jevtana 105 -20.9 % -21.6 % 63 1.6 % 20 -58.3 % 22 -4.3 % Fasturtec 37 -9.5 % -11.9 % 22 -17.9 % 12 9.1 % 3 0.0 % Libtayo 35 61.9 % 66.7 % — 0.0 % 28 47.4 % 7 200.0 % Sarclisa 48 276.9 % 269.2 % 18 111.1 % 17 750.0 % 13 550.0 % Oncology 225 8.1 % 7.1 % 103 6.0 % 77 -3.8 % 45 46.7 % Alprolix 101 -6.4 % -7.3 % 83 5.0 % — 0.0 % 18 -37.9 % Eloctate 144 -4.6 % -5.3 % 111 3.7 % — 0.0 % 33 -25.0 % Cablivi 42 32.3 % 35.5 % 19 -9.5 % 22 120.0 % 1 0.0 % Rare Blood Disorder 287 -1.4 % -1.7 % 213 2.9 % 22 120.0 % 52 -30.1 % Specialty Care 3,287 20.2 % 19.4 % 2,059 21.4 % 689 17.2 % 539 19.6 % Lantus 622 -5.9 % -5.3 % 199 -20.9 % 113 -11.1 % 310 10.1 % Toujeo 239 11.1 % 10.6 % 72 9.1 % 96 6.7 % 71 20.0 % Soliqua/iGlarLixi 51 27.5 % 27.5 % 30 25.0 % 7 16.7 % 14 40.0 % 0thers Diabetes 211 -6.6 % -7.0 % 39 -23.1 % 61 -3.2 % 111 -0.9 % Diabetes 1,123 -1.7 % -1.5 % 340 -13.4 % 277 -3.2 % 506 9.3 % Lovenox 383 4.4 % 4.9 % 9 14.3 % 166 -1.8 % 208 9.5 % Plavix 222 6.3 % 8.3 % 2 -33.3 % 28 -6.9 % 192 9.2 % Multaq 79 0.0 % 0.0 % 70 1.4 % 5 -16.7 % 4 0.0 % Praluent 59 18.0 % 18.0 % — -100.0 % 41 36.7 % 18 200.0 % Aprovel 107 -21.8 % -19.5 % 4 -42.9 % 19 -13.0 % 84 -22.3 % Mozobil 60 7.1 % 7.1 % 33 3.1 % 16 7.1 % 11 20.0 % Thymoglobulin 91 4.6 % 4.6 % 52 1.9 % 9 0.0 % 30 11.5 % Generics 172 -10.9 % -10.9 % 26 -40.5 % 3 0.0 % 143 -2.7 % Others 1,064 -4.0 % -2.9 % 96 -10.2 % 335 -9.2 % 633 0.2 % Cardiovascular & Established Rx Products 2,237 -2.1 % -1.2 % 292 -12.5 % 622 -4.8 % 1,323 2.0 % Industrial Sales 208 2.5 % 2.0 % 9 -60.0 % 186 13.4 % 13 -25.0 % General Medicines 3,568 -1.7 % -1.1 % 641 -14.3 % 1,085 -1.6 % 1,842 3.6 % Pharmaceuticals 6,855 7.8 % 7.8 % 2,700 10.5 % 1,774 4.9 % 2,381 6.9 % Polio / Pertussis / Hib 563 1.8 % 1.8 % 124 6.8 % 79 -11.2 % 360 3.5 % Adult Booster Vaccines 158 4.6 % 4.6 % 105 14.1 % 36 -7.7 % 17 -15.0 % Meningitis / Pneumonia 253 18.7 % 18.2 % 218 19.7 % — 0.0 % 35 12.9 % Influenza Vaccines 1,339 25.5 % 25.7 % 982 18.1 % 247 87.8 % 110 5.9 % Travel and Other Endemic Vaccines 82 16.9 % 15.5 % 34 100.0 % 12 200.0 % 36 -26.0 % Vaccines 2,422 16.5 % 16.6 % 1,488 18.5 % 374 41.8 % 560 0.0 % Allergy 142 17.4 % 17.4 % 92 13.6 % 8 -11.1 % 42 35.5 % Cough, Cold and Flu 94 4.4 % 4.4 % — 0.0 % 45 -10.2 % 49 22.0 % Pain Care 290 18.2 % 17.4 % 53 23.3 % 127 9.5 % 110 27.3 % Digestive Wellness 282 16.0 % 16.0 % 29 16.0 % 97 9.0 % 156 20.9 % Physical Wellness 85 -7.7 % -6.6 % — 0.0 % 7 0.0 % 78 -8.3 % Mental Wellness 53 8.2 % 8.2 % 11 0.0 % 23 4.3 % 19 20.0 % Personal Care 135 5.4 % 4.7 % 101 9.7 % 1 0.0 % 33 -8.3 % Non-Core / Others 74 4.2 % 4.2 % 3 -233.3 % 27 -16.1 % 44 2.3 % Consumer Healthcare 1,155 11.1 % 11.0 % 289 16.4 % 335 3.1 % 531 13.9 % Company 10,432 10.1 % 10.1 % 4,477 13.4 % 2,483 8.9 % 3,472 6.7 % Appendix 1: 2021 first nine months net sales by GBU, franchise, geographic region and product First 9M 2021 (€ million) Total Sales % CER % reported United States % CER Europe % CER Rest of the world % CER Dupixent 3,700 52.5 % 45.0 % 2,801 46.3 % 462 70.1 % 437 85.0 % Aubagio 1,477 -1.7 % -6.1 % 994 -6.2 % 386 10.0 % 97 8.7 % Lemtrada 63 -27.2 % -31.5 % 29 -36.7 % 18 -32.0 % 16 5.6 % Kevzara 196 15.3 % 11.4 % 99 13.0 % 65 18.2 % 32 17.2 % Neurology & Immunology 1,736 -1.4 % -5.7 % 1,122 -6.0 % 469 8.6 % 145 10.1 % Cerezyme 502 1.1 % -5.3 % 128 2.3 % 183 -2.1 % 191 3.3 % Cerdelga 187 10.9 % 6.9 % 97 7.2 % 77 13.2 % 13 30.0 % Myozyme 749 8.4 % 5.0 % 283 11.5 % 305 4.5 % 161 10.5 % Fabrazyme 621 5.7 % 0.6 % 291 0.6 % 164 10.1 % 166 11.3 % Aldurazyme 180 7.3 % 1.7 % 39 7.7 % 63 6.8 % 78 7.6 % Rare Disease 2,308 6.1 % 1.4 % 839 5.6 % 794 5.2 % 675 8.0 % Jevtana 345 -10.9 % -14.8 % 182 4.3 % 95 -32.1 % 68 -8.9 % Fasturtec 111 1.8 % -2.6 % 65 -4.1 % 34 9.7 % 12 20.0 % Libtayo 94 95.8 % 95.8 % — 0.0 % 76 76.7 % 18 260.0 % Sarclisa 122 605.6 % 577.8 % 46 250.0 % 44 2100.0 % 32 1600.0 % Oncology 672 19.3 % 14.9 % 293 14.7 % 249 15.3 % 130 41.7 % Alprolix 301 -4.8 % -10.1 % 245 8.3 % — 0.0 % 56 -38.3 % Eloctate 422 -7.3 % -12.4 % 327 1.8 % — 0.0 % 95 -29.3 % Cablivi 126 56.6 % 51.8 % 62 22.2 % 62 113.8 % 2 0.0 % Rare Blood Disorder 849 -0.4 % -5.7 % 634 6.0 % 62 113.8 % 153 -32.1 % Specialty Care 9,265 19.2 % 13.6 % 5,689 19.6 % 2,036 19.5 % 1,540 17.4 % Lantus 1,911 -4.1 % -7.9 % 628 -7.8 % 359 -11.8 % 924 2.1 % Toujeo 739 7.9 % 3.8 % 192 -2.4 % 291 4.7 % 256 21.3 % Soliqua/iGlarLixi 141 28.7 % 22.6 % 83 23.9 % 21 23.5 % 37 44.4 % 0thers Diabetes 653 -3.7 % -7.6 % 126 -11.2 % 191 -3.5 % 336 -0.6 % Diabetes 3,444 -0.6 % -4.5 % 1,029 -5.3 % 862 -4.2 % 1,553 5.0 % Lovenox 1,151 19.1 % 15.7 % 24 13.6 % 534 15.0 % 593 23.1 % Plavix 707 1.0 % -0.8 % 7 0.0 % 88 -7.4 % 612 2.3 % Multaq 230 4.3 % -1.3 % 202 4.9 % 17 -5.6 % 11 10.0 % Praluent 163 -15.8 % -16.8 % 5 -92.7 % 116 34.9 % 42 53.6 % Aprovel 307 -29.4 % -30.1 % 7 -63.2 % 66 -11.8 % 234 -31.4 % Mozobil 170 13.5 % 9.7 % 93 8.9 % 45 10.0 % 32 36.0 % Thymoglobulin 263 16.1 % 11.4 % 153 16.4 % 25 13.6 % 85 16.2 % Generics 566 -0.3 % -7.8 % 96 -12.8 % 7 0.0 % 463 2.7 % Others 3,197 -5.0 % -7.6 % 254 -14.0 % 1,032 -11.2 % 1,911 0.1 % Cardiovascular & Established Rx Products 6,754 -1.0 % -4.1 % 841 -10.3 % 1,930 -2.0 % 3,983 1.8 % Industrial Sales 588 4.2 % 2.1 % 33 -32.7 % 521 15.8 % 34 -45.6 % General Medicines 10,786 -0.6 % -3.9 % 1,903 -8.2 % 3,313 -0.2 % 5,570 2.1 % Pharmaceuticals 20,051 7.7 % 3.5 % 7,592 11.1 % 5,349 6.5 % 7,110 5.1 % Polio / Pertussis / Hib 1,616 3.1 % 0.2 % 365 29.3 % 224 -10.4 % 1,027 -1.1 % Adult Booster Vaccines 364 8.7 % 5.8 % 218 21.3 % 102 -9.7 % 44 2.3 % Meningitis / Pneumonia 567 36.2 % 30.6 % 425 43.1 % 1 0.0 % 141 18.9 % Influenza Vaccines 1,535 23.9 % 23.4 % 982 16.3 % 265 94.1 % 288 11.8 % Travel and Other Endemic Vaccines 215 -1.3 % -4.4 % 70 23.3 % 25 -40.5 % 120 0.0 % Vaccines 4,359 13.8 % 11.4 % 2,114 24.3 % 618 13.6 % 1,627 2.6 % Allergy 485 2.2 % -3.4 % 292 5.8 % 42 -6.7 % 151 -1.9 % Cough, Cold and Flu 204 -30.9 % -32.2 % — 0.0 % 91 -42.4 % 113 -18.2 % Pain Care 818 7.3 % 2.8 % 144 8.5 % 377 5.3 % 297 9.2 % Digestive Wellness 855 21.8 % 16.5 % 90 57.4 % 297 6.4 % 468 27.3 % Physical Wellness 244 -5.7 % -7.9 % — 0.0 % 20 5.3 % 224 -6.5 % Mental Wellness 160 16.8 % 11.9 % 34 5.9 % 78 15.9 % 48 27.5 % Personal Care 387 2.8 % -3.0 % 292 3.3 % 3 50.0 % 92 0.0 % Non-Core / Others 204 -5.8 % -9.3 % 7 700.0 % 80 -26.2 % 117 6.8 % Consumer Healthcare 3,357 4.2 % -0.2 % 859 10.0 % 988 -4.6 % 1,510 7.2 % Company 27,767 8.2 % 4.2 % 10,565 13.4 % 6,955 5.3 % 10,247 5.0 % Appendix 2: Business net income statement Third Quarter 2021 Pharmaceuticals Vaccines Consumer Healthcare Other(1) Total Group € million Q3 2021 Q3 2020 Change Q3 2021 Q3 2020 Change Q3 2021 Q3 2020 Change Q3 2021 Q3 2020 Change Q3 2021 Q3 2020 Change Net sales 6,855 6,361 7.8% 2,422 2,077 16.6% 1,155 1,041 11.0% — — —% 10,432 9,479 10.1% Other revenues 44 28 57.1% 339 359 -5.6% 14 13 7.7% — — —% 397 400 -0.7% Cost of Sales (1,744) (1,715) 1.7% (1,017) (1,018) -0.1% (422) (361) 16.9% (55) (65) -15.4% (3,238) (3,159) 2.5% As % of net sales (25.4)% (27.0)% (42.0)% (49.0)% (36.5)% (34.7)% (31.0)% (33.3)% Gross Profit 5,155 4,674 10.3% 1,744 1,418 23.0% 747 693 7.8% (55) (65) -15.4% 7,591 6,720 13.0% As % of net sales 75.2% 73.5% 72.0% 68.3% 64.7% 66.6% 72.8% 70.9% Research and development expenses (1,104) (980) 12.7% (185) (178) 3.9% (35) (37) -5.4% (119) (126) -5.6% (1,443) (1,321) 9.2% As % of net sales (16.1)% (15.4)% (7.6)% (8.6)% (3.0)% (3.6)% (13.8)% (13.9)% Selling and general expenses (1,281) (1,151) 11.3% (198) (193) 2.6% (327) (330) -0.9% (461) (508) -9.3% (2,267) (2,182) 3.9% As % of net sales (18.7)% (18.1)% (8.2)% (9.3)% (28.3)% (31.7)% (21.7)% (23.0)% Other current operating income/expenses (329) (190) 2 (2) 77 (3) (39) 13 (289) (182) Share of profit/loss of associates* and joint ventures (5) (1) (3) 2 3 — — — (5) 1 Net income attributable to non controlling interests (27) (8) (1) — (1) (1) — — (29) (9) Business operating income (2) 2,409 2,344 2.8% 1,359 1,047 29.8% 464 322 44.1% (674) (686) -1.7% 3,558 3,027 17.5% As % of net sales 35.1% 36.8% 56.1% 50.4% 40.2% 30.9% 34.1% 31.9% Financial income and expenses (85) (76) Income tax expenses (737) (652) Tax rate** 21.0% 22.0% Business net income 2,736 2,299 19.0% As % of net sales 26.2% 24.3% Business earnings / share(in euros)*** 2.18 1.83 19.1% * Net of tax. ** Determined on the basis of Business income before tax, associates, and non-controlling interests. *** Based on an average number of shares outstanding of 1,254.5 million in the third quarter of 2021 and 1,255.7 million in the third quarter of 2020. (1) Other includes the cost of global support functions (Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc…). (2) The 2020 items have been represented in order to take into account the reallocation of certain expenses, in particular the IT costs related to the new Digital organization, which were previously allocated to the Pharmaceuticals, Vaccines and Consumer Health Care segments and are now accounted for under "Other". 9 months 2021 Pharmaceuticals Vaccines Consumer Healthcare Other(1) Total Group € million 9M 2021 9M 2020 Change 9M 2021 9M 2020 Change 9M 2021 9M 2020 Change 9M 2021 9M 2020 Change 9M 2021 9M 2020 Change Net sales 20,051 19,381 3.5% 4,359 3,913 11.4% 3,357 3,365 (0.2)% — — — 27,767 26,659 4.2% Other revenues 152 98 55.1% 800 833 (4.0)% 41 43 (4.7)% — — — 993 974 2.0% Cost of Sales (5,147) (5,121) 0.5% (2,271) (2,194) 3.5% (1,175) (1,142) 2.9% (186) (209) (11.0)% (8,779) (8,666) 1.3% As % of net sales (25.7)% (26.4)% (52.1)% (56.1)% (35.0)% (33.9)% —% (31.6)% (32.5)% Gross Profit 15,056 14,358 4.9% 2,888 2,552 13.2% 2,223 2,266 (1.9)% (186) (209) (11.0)% 19,981 18,967 5.3% As % of net sales 75.1% 74.1% 66.3% 65.2% 66.2% 67.3% — 72.0% 71.1% Research and development expenses (3,145) (3,045) 3.3% (501) (497) 0.8% (104) (106) (1.9)% (356) (365) (2.5)% (4,106) (4,013) 2.3% As % of net sales (15.7)% (15.7)% (11.5)% (12.7)% (3.1)% (3.2)% — (14.8)% (15.1)% Selling and general expenses (3,761) (3,539) 6.3% (557) (562) (0.9)% (1,027) (1,074) (4.4)% (1,452) (1,614) (10.0)% (6,797) (6,789) 0.1% As % of net sales (18.8)% (18.3)% (12.8)% (14.4)% (30.6)% (31.9)% — (24.5)% (25.5)% Other current operating income/expenses (795) (340) 123 2 100 18 (17) (117) (589) (437) Share of profit/loss of associates* and joint ventures 8 3 5 2 8 7 — — 21 12 Net income attributable to non controlling interests (43) (25) (1) — (5) (5) — — (49) (30) Business operating income (2) 7,320 7,412 (1.2)% 1,957 1,497 30.7% 1,195 1,106 8.0% (2,011) (2,305) (12.8)% 8,461 7,710 9.7% As % of net sales 36.5% 38.2% 44.9% 38.3% 35.6% 32.9% 30.5% 28.9% Financial income and expenses (246) (243) Income tax expenses (1,731) (1,647) Tax rate** 21.0% 22.0% Business net income 6,484 5,820 11.4% As % of net sales 23.4% 21.8% Business earnings / share(in euros)*** 5.18 4.64 11.6% * Net of tax. ** Determined on the basis of Business income before tax, associates, and non-controlling interests. *** Based on an average number of shares outstanding of 1,251.7 million in the first nine months of 2021 and 1,253 million in the first nine months of 2020. (1) Other includes the cost of global support functions (Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc…). (2) The 2020 items have been represented in order to take into account the reallocation of certain expenses, in particular the IT costs related to the new Digital organization, which were previously allocated to the Pharmaceuticals, Vaccines and Consumer Health Care segments and are now accounted for under "Other". Appendix 3: Consolidated income statements € million Q3 2021 Q3 2020 9M 2021 9M 2020 Net sales 10,432 9,479 27,767 26,659 Other revenues 397 400 993 974 Cost of sales (3,238) (3,176) (8,779) (8,719) Gross profit 7,591 6,703 19,981 18,914 Research and development expenses (1,443) (1,321) (4,106) (4,013) Selling and general expenses (2,267) (2,182) (6,797) (6,789) Other operating income 259 242 668 523 Other operating expenses (548) (424) (1,257) (1,117) Amortization of intangible assets (385) (404) (1,160) (1,287) Impairment of intangible assets (1) 1 (2) (177) (325) Fair value remeasurement of contingent consideration 5 22 1 76 Restructuring costs and similar items (167) (110) (494) (868) Other gains and losses, and litigation (2) (4) — (4) 136 Gain on Regeneron investment as result of transaction completed on May 29th, 2020 (3) — — — 7,382 Operating income 3,042 2,524 6,655 12,632 Financial expenses (87) (91) (276) (289) Financial income 2 15 30 46 Income before tax and associates and joint ventures 2,957 2,448 6,409 12,389 Income tax expense (609) (490) (1,291) (1,484) Share of profit/(loss) of associates and joint ventures (5) 1 21 355 Net income 2,343 1,959 5,139 11,260 Net income attributable to non-controlling interests 26 7 46 27 Net income attributable to equity holders of Sanofi 2,317 1,952 5,093 11,233 Average number of shares outstanding (million) 1,254.5 1,255.7 1,251.7 1,253.0 IFRS Earnings per share (in euros) 1.85 1.55 4.07 8.96 (1) In 2021 and 2020, mainly related to Sutimlimab impairments. (2) In 2020, includes mainly the gain on the sale of operations related to the Seprafilm product to Baxter. (3) In 2020, this line includes the pre-tax income from the sale of Regeneron shares following the public offer for sale and Regeneron's repurchase on May 29, 2020. This amount includes the gain related to the remeasurement at fair value of the 400,000 retained shares that could be used to finance the R&D collaboration under the letter of agreement dated 2018. Appendix 4: Reconciliation of Net income attributable to equity holders of Sanofi to Business net income € million Q3 2021 Q3 2020 9M 2021 9M 2020 Net income attributable to equity holders of Sanofi 2,317 1,952 5,093 11,233 Amortization of intangible assets (1) 385 404 1,160 1,287 Impairment of intangible assets (2) (1) 2 177 325 Fair value remeasurement of contingent consideration (5) (22) (1) (76) Expenses arising from the impact of acquisitions on inventories — 17 — 53 Restructuring costs and similar items 167 110 494 868 Other gains and losses, and litigation (3) 4 — 4 (136) Gain on sale of Regeneron shares on May 29, 2020 (4) — — — (7,225) Tax effect of the items listed above: (129) (162) (440) (163) Amortization and impairment of intangible assets (90) (122) (320) (424) Fair value remeasurement of contingent consideration (1) (1) 2 1 Expenses arising from the impact of acquisitions on inventories — (3) — (8) Restructuring costs and similar items (37) (29) (121) (261) Gain on sale of Regeneron shares on May 29, 2020 — — — 475 Other tax effects (1) (7) (1) 54 Share of items listed above attributable to non-controlling interests (2) (2) (3) (3) Restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures — — — (30) Effect of discontinuation of use of equity method for Regeneron investment (5) — — — (313) Business net income 2,736 2,299 6,484 5,820 IFRS earnings per share (6) (in euros) 1.85 1.55 4.07 8.96 (1) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €361 million in the third quarter of 2021 and €383 million in the third quarter of 2020. (2) In 2021 and 2020, mainly related to Sutimlimab impairments. (3) In 2020, includes mainly the gain on the sale of operations related to the Seprafilm product to Baxter. (4) This line includes the result of the sale of 13 million of Regeneron’s shares as part of the public offering and of the 9.8 million of its shares repurchased by Regeneron. The amount does not include the gain related to the remeasurement at fair value at this date of the 400,000 retained shares. (5) Our non-GAAP indicator (Business Net Income) does not include the share of income related to equity accounting from Regeneron since it ceased to be an associate on May 29, 2020. As a result, this line reflects that exclusion up to this date. (6) Q3: Based on an average number of shares outstanding of 1,254.5 million in the third quarter of 2021 and 1,255.7 million in the third quarter of 2020. 9M : Based on an average number of shares outstanding of 1,251.7 million in the first nine months of 2021 and 1,253 million in the first nine months of 2020. Appendix 5: Change in net debt € million 9M 2021 9M 2020 (1) Business net income 6,484 5,820 Depreciation & amortization & impairment of property, plant and equipment and software 1,102 1,125 Other items 117 592 Operating cash flow 7,703 7,537 Changes in Working Capital 218 (933) Acquisitions of property, plant and equipment and software (953) (847) Free cash flow before restructuring, acquisitions and disposals 6,968 5,757 Acquisitions of intangibles assets, investments and other long-term financial assets (2) (1,093) (447) Restructuring costs and similar items paid (781) (660) Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes (2) 461 802 Free cash flow 5,555 5,452 Acquisitions of investments in consolidated undertakings including assumed debt (3) (3,385) (5,767) Proceeds from Sale of Regeneron Shares on May 29,2020 net of taxes — 10,332 Issuance of Sanofi shares 175 194 Acquisition of treasury shares (140) (361) Dividends paid to shareholders of Sanofi (4,008) (3,937) Other items 166 (450) Change in net debt (1,637) 5,463 Beginning of period 8,790 15,107 Closing of net debt 10,427 9,644 (1) Excluding any effect of equity method accounting for Regeneron investment for comparison purposes. (2) Free cash flow includes investments and divestments not exceeding a cap of €500 million per transaction (inclusive of all payments related to the transaction). (3) Includes transactions that are above a cap of €500 million per transaction (inclusive of all payments related to the transaction). Appendix 6: Currency sensitivity 2021 business EPS currency sensitivity Currency Variation Business EPS Sensitivity U.S. Dollar +0.05 USD/EUR -EUR 0.13 Japanese Yen +5 JPY/EUR -EUR 0.02 Chinese Yuan +0.2 CNY/EUR -EUR 0.02 Brazilian Real +0.4 BRL/EUR -EUR 0.01 Russian Ruble +10 RUB/EUR -EUR 0.02 Currency exposure on Q3 2021 sales Currency Q3 2021 US $ 43.8 % Euro € 20.1 % Chinese Yuan 7.1 % Japanese Yen 3.9 % Brazilian Real 1.7 % Canadian $ 1.6 % British Pound 1.5 % Mexican Peso 1.3 % Russian ruble 1.3 % South Korean won 1.1 % Others 16.6 % Currency average rates Q3 2020 Q3 2021 Change 9M 2020 9M 2021 Change €/$ 1.17 1.18 +0.8 % 1.12 1.20 +6.5 % €/Yen 124.05 129.79 +4.6 % 120.84 129.80 +7.4 % €/Yuan 8.09 7.63 -5.7 % 7.87 7.74 -1.60 % €/Real 6.29 6.16 -2.0 % 5.71 6.38 +11.8 % €/Ruble 86.28 86.60 +0.4 % 79.87 88.60 +10.9 % Appendix 7: Definitions of non-GAAP financial indicators Company sales at constant exchange rates (CER) When we refer to changes in our net sales “at constant exchange rates” (CER), this means that we exclude the effect of changes in exchange rates. We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period. Reconciliation of net sales to Company sales at constant exchange rates for the third quarter and In the first nine months 2021 € million Q3 2021 9M 2021 Net sales 10,432 27,767 Effect of exchange rates — (1,075) Company sales at constant exchange rates 10,432 28,842 Business net income Sanofi publishes a key non-GAAP indicator. Following the Regeneron shares transaction that was completed on May 29, 2020, the definition of the non-GAAP financial measure “Business net income” has been revised such that Share of profit/(loss) from investments accounted for using the equity method excludes the effects of applying the equity method to the investment in Regeneron. The comparative periods of 2019 presented have been restated to reflect that adjustment. Business net income is defined as net income attributable to equity holders of Sanofi excluding: amortization of intangible assets, impairment of intangible assets, fair value remeasurement of contingent consideration related to business combinations or to disposals, other impacts associated with acquisitions (including impacts of acquisitions on associates and joint ventures), restructuring costs and similar items(1), other gains and losses (including gains and losses on disposals of non-current assets(1)), costs or provisions associated with litigation(1), gain on Regeneron investment as a result of the transaction completed on May 29, 2020 (the amount does not include the gain related to the remeasurement at fair value at this date of the 400,000 retained shares), tax effects related to the items listed above as well as effects of major tax disputes, effect of equity method accounting for Regeneron investment (excluded from Business net income as a consequence of the sale of the entire equity investment in Regeneron (with the exception of 400,000 shares retained by Sanofi) on May 29th 2020, net income attributable to non-controlling interests related to the items listed above. (1) Reported in the line items Restructuring costsand similar items and Gains and losses on disposals, and litigation, which are defined in Notes B.19. and B.20. to our consolidated financial statements. Free cash flow Free cash flow is a non-GAAP financial indicator which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from the Company’s operations that is available for strategic investments1 (net of divestments1), for debt repayment, and for capital return to shareholders. Free Cash Flow is determined from the Business Net Income adjusted for depreciation, amortization and impairment, share of profit/loss in associates and joint ventures net of dividends received, gains & losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. It comprises net changes in working capital, capital expenditures and other asset acquisitions2 net of disposal proceeds2, and payments related to restructuring and similar items. Free cash flow is not defined by IFRS and it is not a substitute measure for the IFRS aggregate net cash flows in operating activities. 1 Amount of the transaction above a cap of €500 million per transaction (inclusive of all payments related to the transaction). 2 Not exceeding a cap of €500 million per transaction (inclusive of all payments related to the transaction). 1See Appendix 7 for definitions of financial indicators. 2Sanofi has prioritized core assets in its General Medicines portfolio with differentiated and/or established profiles that have significant opportunity for growth in key markets. Core assets include Toujeo, Soliqua, Praluent, Multaq, Lovenox, Plavix and others for total sales of €5.6bn in 2020 3API and Drug Product manufacturing in Sanofi sites for third party 4 Announced on September 8, 2021; Subject to satisfaction or waiver of customary closing conditions, Sanofi expects to complete the acquisition in Q4 2021 5Net zero is achieved when company emissions of greenhouse gases to the atmosphere are balanced by removals elsewhere over a specified period. 6Carbon neutrality is achieved when company emissions of greenhouse gases to the atmosphere are balanced by reduction or avoidance elsewhere over a specified period. 7RE100 is a global initiative bringing together the world's most influential businesses committed to 100% renewable electricity 8See Appendix 3 for 2021 third-quarter consolidated income statement; see Appendix 7 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income. 9Not exceeding €500 million per transaction (inclusive of all payments related to the transaction). 10non-GAAP financial measure (definition in Appendix 7). Attachment Press Release Q3 2021

CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“H1 2021”). SUMMARY PERFORMANCE Reported Adjusted1 H1 2021 £m H1 2020 £m H1 2021 £m H1 2020 £m Revenue 147.5 138.2 147.5 138.2 Gross profit margin, % 70.9% 69.7% 70.9% 69.7% Operating profit 15.5 26.6 23.6 33.4 Profit Before Tax (PBT) 13.8 26.0 21.9 32.8 Diluted earnings per share (EPS) (pence) 5.3p 12.6p 8.1p 13.0p Net Cash* 211.9 88.5 211.9 88.5 * Net Cash comprises cash and cash equivalents less borrowings. FINANCIAL HIGHLIGHTS Total revenue growth of 6.7% on a reported basis and 8.3% at Constant Exchange Rates (CER)1 • Catalogue revenue of £139.0m, growth of 7.8% at CER • Custom Products & Licensing (CP&L) revenue of £8.5m, growth of 15.9% at CER • Total in-house product revenue growth of 24.5% at CER (includes CP&L) (H1 2020: 11.3%) Gross margin increased 120 basis points, benefiting from the contribution of higher margin in-house products Operating profit of £15.5m (H1 2020: £26.6m) and adjusted1 operating profit of £23.6m (H1 2020: £33.4m), equating to an adjusted operating margin of 16.0% (H1 2020: 24.2%) reflecting planned investments to support the Group’s long-term growth strategy, as well as the impact of COVID-19 Reported diluted EPS of 5.3p (H1 2020: 12.6p) and adjusted1 diluted EPS of 8.1p (H1 2020: 13.0p) reflecting the decrease in operating profit and increase in the number of ordinary shares in issue Net cash inflow from operating activities of £33.9m (H1 2020: £39.6m), ending the period with a net cash position of £211.9m (H1 2020: £88.5m) STRATEGIC & OPERATIONAL HIGHLIGHTS Customers gradually returned to labs in H1, although according to industry research, almost 60% of life science labs were still operating below normal capacity through December 2020 Improved customer engagement levels, reflecting our ongoing focus on supporting customers through the pandemic • Average customer transactional Net Promotor Score (tNPS) in the first six months of +59, up 7% pts year-on-year Employee engagement remains high as we continue to support the health and wellbeing of our teams • Externally recognized by Glassdoor, the employer review website, as the 3rd best place to work in the UK in 2020 and the 2nd highest rated CEO of a UK business during the pandemic Delivered operational progress across all areas of our strategic growth plan, including: • Innovated and published over 2,500 new in-house recombinant antibody products and expanded our in-house conjugation, recombinant proteins and engineered cell line ranges • New in-house product introductions significantly up on H1 2020, although certain product development pipelines have slowed due to reduced lab capacity across our global facilities resulting from COVID-19 restrictions • In-house product contribution increased to approximately 53% of catalogue revenue (H1 2020: 45%) and 55% of total revenue (including CP&L) (H1 2020: 48%) • Initiated over 40 partnership agreements with biopharma and diagnostic organizations, with the number of commercialized antibodies rising to over 560 (FY2020: 479) • Further progressed our multi-year program to upgrade the Group’s digital and physical infrastructure Continued to generate value from recent acquisitions, with overall sales ahead of expectations Completed secondary US listing on Nasdaq (in addition to the current listing on AIM in the UK), raising net proceeds of £126.5m Published first ESG Impact Report in November 2020, setting out our sustainability framework Post period end, appointed Bessie Lee and Mark Capone as Non-Executive Directors to the Board CHANGE OF FISCAL YEAR END Before the end of this fiscal year, the Board intends to change the Company’s accounting reference date (fiscal year end). The Board has undertaken a review of the appropriate year end for the Company and has decided that this year would be the right time to move the fiscal year end from 30 June to 31 December. Following this change, the Company’s near-term reporting calendar will be as follows: Unaudited results for the six- and twelve-month periods to 30 June 2021 to be announced in September 2021 Audited results for the twelve and 18-month periods to 31 December 2021 to be announced in March 2022 Publication of the 2021 annual report and accounts expected before the end of April 2022 Furthermore, assuming the change in accounting reference date is implemented as expected, the Company plans to hold future AGMs in the second calendar quarter of each year, and will hold a general meeting in the summer to review necessary authorities that would otherwise expire before the next AGM. COVID-19 UPDATE AND IMPLICATIONS FOR LONG-TERM GROWTH OUTLOOK TO 2024 Fundamental drivers of the life science research market remain attractive with stable public funding and an increasing emphasis on proteomics and clinically relevant biologics Implementation of Abcam’s strategy remains within the Board’s expectations of timing, costs, and milestones. We remain confident in realizing growth from these investments and generating an attractive return on capital employed as we gain operational leverage, normalize capital investment, and generate more of our own product at higher gross margins COVID-19 pandemic controls continue to constrain researcher access to approximately 50% of labs globally. These constraints are limiting scientific discovery capacity and we observe demand in those labs well below historic levels With over 15 months of operational experience through the pandemic, we remain cautious in our assessment of when laboratory activity and demand will return to full strength We are updating our long-term outlook to reflect a broader range of potential outcomes than originally outlined in November 2019, with a range of revenue outcomes for the end of calendar 2024 of £425 – 500m (at current exchange rates) We expect to provide further information when laboratory activity and demand return to normal levels Commenting on the first half performance, Alan Hirzel, Abcam’s Chief Executive Officer, said: “We delivered over 8% revenue growth at constant exchange rates in the first half year as we started to see more activity in our customers’ labs. Whilst we haven’t yet observed a return to normal demand, we are encouraged by the 25% growth in our in-house products and the long-term outlook for Abcam. We remain confident in our growth strategy and are committed to investing in innovation and building an increasingly strong and sustainable global business.” Analyst and investor meeting and webcast: Abcam will host a conference call and webcast for analysts and investors today at 14:00 GMT/ 09:00 EST. For details, and to register, please visit corporate.abcam.com/investors/reports-presentations For further details please contact FTI Consulting at abcam@fticonsulting.com A recording of the webcast will be made available on Abcam’s website, corporate.abcam.com/investors Notes: These interim results include discussion of alternative performance measures which include revenues calculated at Constant Exchange Rates (CER) and adjusted financial measures. CER results are calculated by applying prior period's actual exchange rates to this period's results. Adjusted financial measures are explained in note 2(c) and reconciled to the most directly comparable measure prepared in accordance with IFRS in note 4 to the interim financial statements. Further detail on the Group's financial performance is set out in the interim financial statements and notes thereto. The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. For further information please contact: Abcam + 44 (0) 1223 696 000 Alan Hirzel, Chief Executive Officer Michael Baldock, Chief Financial Officer James Staveley, Vice President, Investor Relations Numis – Nominated Advisor & Joint Corporate Broker + 44 (0) 20 7260 1000 Garry Levin / Freddie Barnfield / Duncan Monteith J.P. Morgan Cazenove – Joint Corporate Broker + 44 (0) 20 7742 4000 James Mitford / Hemant Kapoor Morgan Stanley – Joint Corporate Broker + 44 (0) 207 425 8000 Tom Perry / Luka Kezic FTI Consulting + 44 (0) 20 3727 1000 Ben Atwell / Natalie Garland-Collins This announcement shall not constitute an offer to sell or solicitation of an offer to buy any securities. This announcement is not an offer of securities for sale in the United States, and the securities referred to herein may not be offered or sold in the United States absent registration except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933, as amended. Any public offering of such securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer, which would contain detailed information about the company and management, as well as financial statements. Forward Looking Statements This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation statements of targets, plans, objectives or goals for future operations, including those related to Abcam’s products, product research, product development, product introductions and sales forecasts; statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; statements regarding future economic and financial performance; statements regarding the scheduling and holding of general meetings and AGMs; statements regarding the assumptions underlying or relating to such statements; statements about Abcam's portfolio and ambitions, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus (“COVID-19”), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavors; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption “Risk Factors” in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on 22 October 2020, which is on the SEC and is available on the SEC website at as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law. Interim management report Introduction Since the arrival of COVID-19 over a year ago, our priorities haven’t changed: protect and support our teams; deliver for customers and support the global scientific effort to understand, diagnose, prevent, and treat the disease. Against the backdrop of the pandemic and a market environment where demand remained well below normal levels, we were pleased to see the level of growth in the first half, particularly as, due to ongoing efforts to raise quality standards, we delisted third-party products which had contributed approximately £4m in revenues in the first half of fiscal 2020. We were also pleased to see the positive impact of our focus on customers, with customer transactional Net Promotor Score (tNPS), a strategic performance indicator of the business, up seven percentage points year-on-year, to +59 (H1 2020: +52) and customer product satisfaction rates at all-time highs. Our core reagents business delivered a solid performance as we continue to focus on providing an increasing range of products to biological pathways of the greatest interest to research and clinical communities. Customer demand for our in-house products was particularly strong, with constant currency sales growth of approximately 25% as scientists sought to maximise efficiency in the lab with high quality and time-saving products including highly validated recombinant antibodies and immunoassays. Our global research and development (R&D) activity continues to focus on driving standards in quality and validation. This differentiates our products, aligns us with the needs of our customers and allows us to deliver on our purpose of serving life scientists to achieve their mission faster. Our more than 1,600 dedicated colleagues around the world have continued to look out for and support each other through what continues to be a challenging period. Our internal employee engagement data, which we undertake on a regular basis, remains at multi-year highs and we were delighted to be externally recognized by Glassdoor as the third highest employee rated employer in the UK. In line with our plans, we continued to invest in our innovation capabilities, systems and processes, facilities, and people during the half, remaining focused on ensuring these investments support our long-term growth aspirations. Underpinning our continued progress is our solid financial position, which was further strengthened by our US listing and equity raise on Nasdaq in October 2020, where we raised net proceeds of £126.5m, providing the foundation to further grow the business organically and through further transactions. Strategic performance indicators Alongside a return to revenue growth, performance against our strategic measures was positive in the period. Strategic Performance Indicator H1 2021 Result Catalogue revenue growth from in-house products (CER) +25.6% (H1 2020: +13.8%) Customer transactional Net Promoter Score (tNPS) +59 (H1 2020: +52) Executing our long-term growth strategy to 2024 We aim to deliver consistent, durable growth and performance in a responsible way, with our activities guided by three goals: Sustain and extend antibody and digital leadership Drive continued expansion into complementary market adjacencies Build organisational scalability and sustain value creation We made progress across each of these areas in the first half, strengthening our position as the partner of choice for our customers and partners. Highlights for each are discussed below. Sustaining and extending antibody and digital leadership We developed and introduced more than 2,500 new recombinant antibody products during the first half. Product development continues to focus on major research areas including immuno-oncology, neuroscience and epigenetics, as well as products to support SARS-CoV-2 research. Products included recombinant RabMAb antibodies, antibody pairs, SimpleStep ELISA kits and new formulations that enable faster labelling and assay development. This was significantly more new product introductions in the first half than during the same period in FY2020, although certain product development pipelines have slowed due to our own need to reduce lab capacity across our global facilities as a result of COVID-19 restrictions. Overall, our portfolio of recombinant antibody and immunoassay products exceeded 24,000 in the half, with revenue from these product categories growing by over 30% (CER). Our work to improve product quality also continued. Our award winning CRISPR gene knockout validation program grew to over 3,500 products, and we validated hundreds of antibodies in new applications to extend their utility for customers. Edigene’s cell line portfolio and Applied Stem Cell’s gene-editing platform, both acquired in FY2020, continue to support these programs and are leading to higher throughput antibody selection and stronger validation. These and other quality initiatives, including the ongoing removal of products that do not meet our standards, led to the Group achieving its highest ever product satisfaction rates for both in-house and third-party products. Alongside product innovation, we continue to make enhancements to our digital marketing and eCommerce sites. Our multi-year plans to upgrade our digital platform achieved notable milestones in the first half, with the opening of a new digital hub in Amsterdam and the commencement of beta-testing of the new platform. Expanding into adjacent markets New product lines We made further progress across each of our focus areas in the half, including conjugation and labelling, recombinant proteins, cell lines and lysates, and imaging and multiplexing consumables. Our conjugation and labelling business – significantly expanded through the acquisition of Expedeon last year – is allowing us to serve the growing need for antibody conjugation and multiplexing solutions, and continues to perform ahead of plan. We also made further operational and commercial progress with our FirePlex® multiplex offering, with the addition of several new biopharma customers and a new high-throughput 1,536 well-plate product launched in January 2021. We completed the build out of our protein development team during the half and are seeing early customer interest in our initial cohort of high-quality, bioactive proteins. Our operational capacity for protein development will be further expanded later this calendar year, with the opening of our Waltham, MA facility. We achieved several milestones in our cell lines business, including opening a new R&D facility in Fremont, California; publishing the Edigene portfolio acquired in FY2020; and introducing our first batch of in-house developed cell lines. Early customer demand for these products is encouraging and includes the extension of our partnership with the Michael J Fox Foundation to include knock-out and knock-in cell line development for Parkinson's research. Partnering with biopharma and ‘Abcam Inside’ Across the translational research and clinical markets, our goal is to be a trusted partner to organisations looking to access our antibodies and antibody expertise for their platforms and clinical development programs. This area of our business continues to develop rapidly and generate strong interest from customers, benefiting from the investments we have made in our innovation capabilities, business development and commercial teams over the last few years. We entered into over 40 new agreements during the first half with new and existing partners, and commercialized almost 100 additional clones through co-development programs, spanning platform, diagnostic and pathology partners. In all, over 560 of our antibodies are now validated for commercial use on third-party platforms or as diagnostic tools, with over 2,000 more undergoing evaluation by partners. These programs are enabling more scientists to access our products whilst also supporting clinical developments that will result in better diagnosis and treatment for patients. Building organisational scalability and sustaining value creation We continue to invest in our business and build scalability into our operational infrastructure including our talent and team capabilities, our manufacturing and logistics footprint, and our IT backbone and digital capabilities to allow us to deliver on our growth plans, increase efficiency and sustain value creation. We continue to benefit from the ERP modules deployed to date, including finance, HR, customer experience and non-stock procurement. Preparations for the deployment of the final stage of our ERP, covering manufacturing and supply chain, remain on track as we moved from the design phase to user testing during the period. We have further invested in building our global footprint. In December 2020, we opened a 16,000 sq. ft. state-of-the-art facility in Fremont, CA to support cell line development and production. Other footprint developments underway include the construction of a new 100,000 sq. ft site in Waltham, MA and upgrades and expansions across our operations in California, Oregon and China. Despite disruption caused by COVID-19, our plans remain on track to complete these enhancements during calendar 2021. We have also continued to make process improvements across our global supply chain, which, together with the automation of manual systems across customer operations, procurement and finance is helping to address constraints, increase product availability, generate efficiencies, and improve customer support levels. Finally, we remain active in our pursuit of strategic acquisitions that will strengthen our competitive position in our core markets and support our expansion into adjacencies. Financial Performance Revenue Total revenue for the first half was £147.5m (H1 2020: £138.2m), representing growth of 6.7% on a reported basis and 8.3% on a constant currency basis. Growth was driven by demand for in-house developed products, with total in-house revenue growth of 24.5% (CER) (including CP&L revenue) to £81.8m (H1 2020: £66.7m), representing 55.5% of total revenue (H1 2020: 48.3%). On a constant currency basis, catalogue revenue, representing 94% of the total, grew 7.8% in the half whilst Custom Products & Licensing (‘CP&L’) revenue grew 15.9%. Catalogue revenue grew mid-single- to double-digits in all regions other than the Americas, where customer laboratory activity has continued to be constrained due to COVID-19. Within CP&L, strong growth in revenue from the supply of products for IVD use, where the Group had experienced delays to certain customer orders in FY2020, as well as growth in income from Royalties and Licenses was partially offset by a decline in revenue from custom projects, which experienced lower customer activity in the period due to COVID-19. Reported revenue H1 2021 H1 2020 Change in reported revenue CER growth H1 2021 % split £’m £’m Catalogue revenue by region: The Americas 51.2 52.7 (2.8%) 0.8% 37% EMEA 39.2 34.4 14.0% 12.4% 28% China 27.3 23.7 15.2% 15.1% 20% Japan 9.9 9.4 5.3% 6.4% 7% Rest of Asia Pacific 11.4 10.4 9.6% 12.8% 8% Catalogue revenue sub-total 139.0 130.6 6.4% 7.8% 100% Custom products and services 2.7 3.3 (18.2%) (16.7%) 32% IVD 2.6 1.4 85.7% 94.2% 31% Royalties and licenses 3.2 2.9 10.3% 15.6% 37% Custom Products & Licensing sub-total 8.5 7.6 11.8% 15.9% 100% Total reported revenue 147.5 138.2 6.7% 8.3% Catalogue revenue by product type: In-house products 73.3 59.1 24.0% 25.6% 53% Third-party products 65.7 71.5 (8.1%) (7.0%) 47% Catalogue revenue sub-total 139.0 130.6 6.4% 7.8% 100% Gross margin Gross margin for the first half was 70.9%, 120 basis points higher than the same period in the prior year (H1 2020: 69.7%) predominantly benefitting from product mix, with a higher percentage of Catalogue revenue generated from in-house products. Operating Costs and Expenses Reported Adjusted* H1 2021 £m H1 2020 £m H1 2021 £m H1 2020 £m Selling, general & administrative expenses (SG&A) 75.4 60.7 70.5 56.1 Research and development expenses (R&D) 13.7 9.0 10.5 6.8 Total operating costs and expenses 89.1 69.7 81.0 62.9 Non-cash costs Depreciation and amortisation (16.0) (13.2) (11.0) (9.8) Share-based compensation (7.3) (5.0) (7.3) (5.0) Total operating costs and expenses excluding non-cash costs 65.8 51.5 62.7 48.1 * Details of items excluded from reported costs and expenses are provided in Adjusting Items below and in note 4 of the interim financial statements. On a reported basis, after the impact of the year-on-year movement in exchange rates, total operating costs and expenses increased by £19.4m or 27.8%, to £89.1m (H1 2020: £69.7m) reflecting greater business activity and planned investments made during the period, predominantly in innovation and our global team. On an adjusted basis, costs and expenses increased £18.1m to £81.0m (H1 2020: £62.9m). Excluding non-cash costs, comprising depreciation and amortisation and share-based compensation, total reported costs increased by 27.8% to £65.8m. On a reported basis, SG&A expenses rose £14.7m or 24.2% to £75.4m (H1 2020: £60.7m) and R&D expenditure, which relates to the development of new products, as well as costs incurred in identifying and implementing production process improvements, increased by £4.7m or 52.2%, to £13.7m net of an R&D tax credit of £0.6m (H1 2020: £0.9m). Increases in reported costs include the following key items: A £16.9m increase in salaries and salary-related costs, predominantly due to increased headcount as well as increased untaken vacation accrual which arises from the impact of COVID-19. The figure also includes an increase in share-based compensation costs of £2.3m; An increase of £2.2m in general administrative costs, to £8.8m which includes an incremental additional £0.8m in respect of insurance costs arising from the Nasdaq listing. The incremental insurance charge for H2 is expected to be £2.0m; An increase in depreciation and amortisation charges of £2.8m, to £16.0m. This includes a £1.0m increase in amortisation of acquired intangibles (included within adjusting items) reflecting the intangible assets acquired with Expedeon in H1 2020, offset by reduced amortisation following the impairment of intangible assets relating to AxioMx in Vitro monoclonal antibody production technology in H2 2020. There was also a £0.8m increase of depreciation on leased assets, following the upgrades and expansion of our geographic footprint; and A total increase of £0.6m across other costs including integration and reorganisation costs and acquisition costs to £1.9m (H1 2020: £1.3m), which are treated as adjusting items. Adjusting Items Total reported expenses of £89.1m for the half includes £8.1m (H1 2020: £6.8m) of costs which are excluded from adjusted expenses. These costs comprise: £1.8m relating to the Oracle Cloud ERP project (H1 2020: £2.1m) £1.9m of integration and reorganisation charges (H1 2020: nil); and £4.4m relating to the amortisation of acquired intangibles (H1 2020: £3.4m) Costs relating to the Oracle Cloud ERP project and amortisation of acquired intangibles are expected to remain at a similar level in the second half of the year. The Group also expects to incur further reorganisation costs associated with the upgrades and expansion of the Group’s geographic footprint in the second half. Note 4 to the interim financial statements sets out a reconciliation between reported and adjusted profit measures. Earnings, Interest and Tax Reported operating profit for the period was £15.5m (H1 2020: £26.6m). Adjusted operating profit was £23.6m (H1 2020: £33.4m), representing an adjusted operating profit margin of 16.0% (H1 2020: 24.2%) reflecting planned investment, the impact of COVID-19, and the step up in non-cash items including depreciation and amortisation and share-based payments. After net finance costs of £1.7m (H1 2020: £0.6m), profit before tax on a reported basis was £13.8m (H1 2020: £26.0m). The Group reported tax of £2.1m (H1 2020: credit £0.1m), equating to an effective rate on reported profits for the first half of 15.2% (H1 2020: -0.4%). Tax on adjusting items totalled £1.8m, resulting in an effective tax rate on adjusted profits of 17.8% (H1 2020: 17.7%). The Group continues to expect that its effective tax will remain around 18% in the near term, although the recently announced proposed increase of the UK corporation tax rate to 25%, commencing 1 April 2023, will impact this. The Group’s effective tax rate remains subject to further changes to the UK corporate tax rate, as well as any changes that may occur in other jurisdictions in which the Group operates. The weighted average number of basic ordinary shares in issue increased by 14.3m in comparison to H1 2020, to 219.6m shares, predominantly due to the placing of new shares in April 2020 and October 2020. Accordingly, basic earnings per share (EPS) for the year was 5.3p (H1 2020: 12.7p), with adjusted basic EPS of 8.2p (H1 2020: 13.2p). Diluted EPS was 5.3p (H1 2020: 12.6p) and adjusted diluted EPS was 8.1p (H1 2020: 13.0p). Note 6 sets out a reconciliation between reported and adjusted EPS. Cash Flow and Net Cash The Group remains highly cash generative at the operating level, although the decline in operating profit meant that cash inflows from operating activities declined to £33.9m (H1 2020: £39.6m). After taxes paid and an increase in net capital expenditure (including cash flows relating to committed capital expenditure), Free Cash Flow was £6.6m (H1 2020: £20.0m). Cash outflows on investing activities were £22.8m (H1 2020: £18.8m), predominantly comprising capital expenditure of £25.1m (H1 2020: £17.1m). Major areas of capital expenditure included £8.5m in respect of global footprint developments (H1 2020: £nil), and £13.6m on intangible assets (H1 2020: £9.2m). Intangible assets included £7.2m in respect of our ERP implementation project and £4.5m of internally developed technology relating to new in-house products. Cash inflows from financing activities totalled £15.0m (H1 2020: £83.6m). This figure was driven by the receipt of net proceeds of £127.0m from issuing new shares, including the placing of 10.3m American Depository Shares in October 2020, partially offset by the repayment of £107.0m of the Group’s revolving credit facility together with other outflows of £5.0m (H1 2020: £2.9m). The Group ended the year with a net cash position of £211.9m (H1 2020: £88.5m). COVID-19 Update and Implications for Long-Term Growth Outlook To 2024 The fundamental drivers of the life science research market remain attractive with stable public funding and an increasing emphasis on proteomics and clinically relevant biologics. In markets and labs where working in the lab is unconstrained, Abcam is seeing high growth in demand, highlighting the long-term and durable growth prospects for the business. Implementation of Abcam’s strategy remains within the Board’s expectations of timing, costs, and milestones. We remain confident in realising growth from these investments and generating an attractive return on capital employed as we gain operational leverage, normalise capital investment, and generate more of our own product at high gross margins. However, COVID-19 pandemic controls are constraining researcher access to approximately 50% of labs globally. These constraints are limiting scientific discovery capacity and we observe demand in those labs well below historic levels. This dynamic is particularly true within academic labs in the US, Abcam’s largest market. With over 15 months of operational experience throughout the pandemic, we have learned to be more cautious in our assessment of when laboratory activity and demand will return to full strength. As we look ahead to the remainder of 2021, we are optimistic that vaccination and pandemic controls will gradually lead to a return to full activity in labs. However, we cannot predict how long this may take to achieve, and therefore believe that the rate of demand growth will remain uncertain throughout this calendar year. With this in mind, we believe the long-term outlook to 2024 for Abcam has a broader range of potential outcomes than we outlined when we announced our five year growth aspirations in November 2019. Our latest view of the range of revenue that could be generated by the business by the end of calendar 2024, is £425 – 500m (at current exchange rates). When laboratory activity and demand return to normal levels, we expect to provide additional information. Alan Hirzel Chief Executive Officer Michael S Baldock Chief Financial Officer 8 March 2021 Forward Looking Statements This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation statements of targets, plans, objectives or goals for future operations, including those related to Abcam’s products, product research, product development, product introductions and sales forecasts; statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; statements regarding future economic and financial performance; statements regarding the scheduling and holding of general meetings and AGMs; statements regarding the assumptions underlying or relating to such statements; statements about Abcam's portfolio and ambitions, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus (“COVID-19”), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavours; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption “Risk Factors” in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on 22 October 2020, which is on the SEC and is available on the SEC website at as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law. Responsibility statement We confirm to the best of our knowledge: the interim financial statements have been prepared in accordance with IAS 34, as adopted by the European Union; the Financial and Operational highlights, Interim Management Report and Interim Financial statements include a fair review of the information required by the Financial Statements Disclosure and Transparency Rules (DTR) 4.2.7R, being an indication of important events that have occurred during the first six months of the financial year and a description of the principal risks and uncertainties for the remaining six months of the year; and the Financial and Operational highlights and Interim Management Report include a fair review of the information required by DTR 4.2.8R, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during the period and also any changes in the related party transactions described in the last Annual Report that could do so. At the date of this statement, the Directors are those listed in the Group's 2019/20 Annual Report and Accounts except for the following changes. Appointed Bessie Lee 28 January 2021 Mark Capone 28 January 2021 By order of the Board Alan Hirzel Chief Executive Officer Michael S Baldock Chief Financial Officer 8 March 2021 Independent review report to Abcam plc Report on the condensed consolidated interim financial statements Our conclusion We have reviewed Abcam plc’s consolidated interim financial statements (the “interim financial statements”) in the interim report of Abcam plc for the 6 month period ended 31 December 2020 (the “period”). Based on our review, nothing has come to our attention that causes us to believe that the interim financial statements are not prepared, in all material respects, in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’, as adopted by the European Union and the AIM Rules for Companies. What we have reviewed The interim financial statements comprise: the consolidated balance sheet as at 31 December 2020; the consolidated income statement and consolidated statement of comprehensive income for the period then ended; the consolidated cash flow statement for the period then ended; the consolidated statement of changes in equity for the period then ended; and the explanatory notes to the interim financial statements. The interim financial statements included in the interim report of Abcam plc have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’, as adopted by the European Union and the AIM Rules for Companies. As disclosed in note 2 to the interim financial statements, the financial reporting framework that has been applied in the preparation of the full annual financial statements of the group is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the European Union. Responsibilities for the interim financial statements and the review Our responsibilities and those of the directors The interim report, including the interim financial statements, is the responsibility of, and has been approved by the directors. The directors are responsible for preparing the interim report in accordance with the AIM Rules for Companies which require that the financial information must be presented and prepared in a form consistent with that which will be adopted in the company’s annual financial statements. Our responsibility is to express a conclusion on the interim financial statements in the interim report based on our review. This report, including the conclusion, has been prepared for and only for the company for the purpose of complying with the AIM Rules for Companies and for no other purpose. We do not, in giving this conclusion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing. What a review of interim financial statements involves We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We have read the other information contained in the interim report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the interim financial statements. PricewaterhouseCoopers LLP Chartered Accountants Cambridge 8 March 2021 Consolidated income statement Six months ended 31 December 2020 Six months ended 31 Dec 2020 (unaudited) Six months ended 31 Dec 2019 (unaudited) Note Adjusted* £m Adjusting items* £m Total £m Adjusted* £m Adjusting items* £m Total £m Revenue 147.5 — 147.5 138.2 — 138.2 Cost of sales (42.9) — (42.9) (41.9) — (41.9) Gross profit 104.6 — 104.6 96.3 — 96.3 Selling, general and administrative expenses (70.5) (4.9) (75.4) (56.1) (4.6) (60.7) Research and development expenses (10.5) (3.2) (13.7) (6.8) (2.2) (9.0) Operating profit 23.6 (8.1) 15.5 33.4 (6.8) 26.6 Finance income 0.2 — 0.2 0.5 — 0.5 Finance costs (1.9) — (1.9) (1.1) — (1.1) Profit before tax 21.9 (8.1) 13.8 32.8 (6.8) 26.0 Tax 5 (3.9) 1.8 (2.1) (5.8) 5.9 0.1 Profit for the period attributable to equity shareholders of the parent 18.0 (6.3) 11.7 27.0 (0.9) 26.1 Earnings per share Basic 6 8.2p 5.3p 13.2p 12.7p Diluted 6 8.1p 5.3p 13.0p 12.6p * Adjusted figures exclude system and process improvement costs, acquisition costs, integration and reorganisation costs, amortisation of acquisition related intangible assets, the tax effect of adjusting items and certain individually significant tax items. Such excluded items are described as “adjusting items”. Further information on these items is shown in note 4. Consolidated statement of comprehensive income Six months ended 31 December 2020 Six months ended 31 Dec 2020 (unaudited) £m Six months ended 31 Dec 2019 (unaudited) £m Profit for the period attributable to equity shareholders of the parent 11.7 26.1 Items that may be reclassified to the income statement in subsequent years Movement on cash flow hedges 1.1 3.3 Exchange differences on translation of foreign operations (17.5) (7.9) Movement in fair value of investment (3.1) 0.2 Tax relating to components of other comprehensive income 0.6 (0.6) Other comprehensive expense for the period (18.9) (5.0) Total comprehensive (expense) / income for the period (7.2) 21.1 Consolidated balance sheet As at 31 December 2020 Notes As at 31 Dec 2020 (unaudited) £m As at 30 Jun 2020 (audited) £m As at 31 Dec 2019 (unaudited) £m Non-current assets Goodwill 184.3 192.8 116.7 Intangible assets 154.5 154.4 108.9 Property, plant and equipment 48.7 43.3 41.0 Right-of-use assets 108.8 121.4 67.2 Investment 10 3.4 7.0 3.1 Deferred tax asset 15.6 13.7 8.1 515.3 532.6 345.0 Current assets Inventories 43.4 40.7 39.5 Trade and other receivables 47.3 44.4 33.9 Current tax receivable 4.6 6.4 12.0 Derivative financial instruments 10 0.3 — 2.1 Cash and cash equivalents 211.9 187.3 189.9 307.5 278.8 277.4 Total assets 822.8 811.4 622.4 Current liabilities Trade and other payables (46.5) (43.8) (39.6) Derivative financial instruments 10 (0.1) (1.2) (0.1) Borrowings 10 — (106.4) (101.4) Lease liabilities (7.1) (7.3) (6.5) Current tax liabilities (1.4) (0.9) (1.1) (55.1) (159.6) (148.7) Net current assets 252.4 119.2 128.7 Non-current liabilities Deferred tax liability (28.1) (28.7) (16.4) Lease liabilities (109.9) (120.5) (67.5) (138.0) (149.2) (83.9) Total liabilities (193.1) (308.8) (232.6) Net assets 629.7 502.6 389.8 Equity Share capital 0.5 0.4 0.4 Share premium account 265.1 138.2 27.8 Merger reserve 68.6 68.6 68.1 Own shares (2.4) (2.5) (2.6) Translation reserve 25.4 42.9 25.4 Hedging reserve 0.2 (0.7) 1.4 Retained earnings 272.3 255.7 269.3 Total equity attributable to the equity shareholders of the parent 629.7 502.6 389.8 Approved by the Board of directors and authorised for issue on 8 March 2021. Consolidated statement of changes in equity Six months ended 31 December 2020 (unaudited) Share capital £m Share premium account £m Merger reserve £m Own shares £m Translation Reserve £m Hedging reserve £m Retained Earnings £m Total £m Balance as at 1 July 2020 0.4 138.2 68.6 (2.5) 42.9 (0.7) 255.7 502.6 Profit for the period — — — — — — 11.7 11.7 Other comprehensive (expense) / income — — — — (17.5) 0.9 (2.3) (18.9) Total comprehensive expense for the period — — — — (17.5) 0.9 9.4 (7.2) Issue of ordinary shares, net of share issue costs 0.1 126.9 — 0.1 — — (0.1) 127.0 Share-based payments inclusive of deferred tax — — — — — — 7.4 7.4 Purchase of own shares — — — — — — (0.1) (0.1) Balance as at 31 December 2020 (unaudited) 0.5 265.1 68.6 (2.4) 25.4 0.2 272.3 629.7 Six months ended 31 December 2019 (unaudited) Share capital £m Share premium account £m Merger reserve £m Own shares £m Translation reserve £m Hedging reserve £m Retained earnings £m Total £m Balance as at 30 June 2019, as previously reported 0.4 27.0 68.1 (2.8) 33.3 (1.3) 260.1 384.8 Implementation of IFRS16 * — — — — — — (2.2) (2.2) Balance as at 1 July 2019, as adjusted 0.4 27.0 68.1 (2.8) 33.3 (1.3) 257.9 382.6 Profit for the period — — — — — — 26.1 26.1 Other comprehensive income / (expense) — — — — (7.9) 2.7 0.2 (5.0) Total comprehensive income for the period — — — — (7.9) 2.7 26.3 21.1 Issue of ordinary shares — 0.8 — 0.2 — — (0.2) 0.8 Share-based payments inclusive of deferred tax — — — — — — 3.1 3.1 Purchase of own shares — — — — — — (0.1) (0.1) Equity dividends — — — — — — (17.7) (17.7) Balance as at 31 December 2019 (unaudited) 0.4 27.8 68.1 (2.6) 25.4 1.4 269.3 389.8 Year ended 30 June 2020 Share capital £m Share premium account £m Merger reserve £m Own shares £m Translation reserve £m Hedging reserve £m Retained earnings £m Total £m Balance as at 30 June 2019, as previously reported 0.4 27.0 68.1 (2.8) 33.3 (1.3) 260.1 384.8 Implementation of IFRS16 * — — — — — — (1.5) (1.5) Balance as at 1 July 2019, as adjusted 0.4 27.0 68.1 (2.8) 33.3 (1.3) 258.6 383.3 Profit for the period — — — — — — 12.5 12.5 Other comprehensive income / (expense) — — — — 9.6 0.6 2.6 12.8 Total comprehensive income for the period — — — — 9.6 0.6 15.1 25.3 Issue of ordinary shares — 111.2 0.5 0.3 — — (0.3) 111.7 Share-based payments inclusive of deferred tax — — — — — — 7.4 7.4 Purchase of own shares — — — — — — (0.1) (0.1) Equity dividends — — — — — — (25.0) (25.0) Balance as at 30 June 2020 (audited) 0.4 138.2 68.6 (2.5) 42.9 (0.7) 255.7 502.6 * Subsequent to the disclosure of the effect of implementation of IFRS 16 which was made in the interim financial statements for the six months ended 31 December 2019, an amendment was made to reduce the transition adjustment to £1.5m. The results to 31 December 2019 have not been restated to reflect this change. Consolidated cash flow statement Six months ended 31 December 2020 Notes Six months ended 31 Dec 2020 (unaudited) £m Six months ended 31 Dec 2019 (unaudited) £m Cash generated from operations 8 33.7 45.5 Net income taxes received / (paid) 0.2 (5.9) Net cash inflow from operating activities * 33.9 39.6 Investing activities Investment income 0.2 0.5 Purchase of property, plant and equipment * (11.5) (7.9) Purchase of intangible assets * (13.6) (9.2) Transfer of cash from escrow in respect of future capital expenditure * 0.4 0.1 Reimbursement of leasehold improvement costs * 1.7 — Purchase of investments — (2.2) Net cash outflow arising from acquisitions — (0.1) Net cash outflow from investing activities (22.8) (18.8) Financing activities Dividends paid 9 — (17.7) Principal element of lease obligations * (3.8) (2.2) Interest element of lease obligations * (0.5) (0.4) Interest paid (0.6) (0.2) Proceeds on issue of shares, net of issue costs 127.0 0.8 Utilisation of revolving credit facility — 103.4 Repayment of revolving credit facility 10 (107.0) — Purchase of own shares (0.1) (0.1) Net cash inflow from financing activities 15.0 83.6 Net increase cash and cash equivalents 26.1 104.4 Cash and cash equivalents at beginning of period 187.3 87.1 Effect of foreign exchange rates (1.5) (1.6) Cash and cash equivalents at end of period (i) 211.9 189.9 Free Cash Flow (ii) 6.6 20.0 (i) Within cash and cash equivalents is £1.3m (H1 2020: £0.6m) of cash relating to employee contributions to the Group’s share scheme ‘AbShare’, which is reserved for the purpose of purchasing shares upon vesting. (ii) Free Cash Flow comprises those items marked * and comprises net cash generated from operating activities less net capital expenditure and decrease in obligations under leases. Notes to the interim financial statements For the six-month period ended 31 December 2020 1. General information This condensed consolidated interim financial statements for the six months ended 31 December 2020 is unaudited and does not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006 but has been reviewed by the auditor. The financial information for the year ended 30 June 2020 does not constitute the Company’s statutory accounts for that period, but has been extracted from those accounts, which were approved by the Board of Directors on 12 September 2020 and have been delivered to the Registrar of Companies. The auditor has reported on those accounts, their opinion was unqualified, did not draw attention to any matters by way of emphasis and did not contain any statement under section 498(2) or (3) of the Companies Act 2006. 2. Basis of preparation The condensed interim financial statements for the six months ended 31 December 2020 included in this interim financial report has been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ (IAS 34) as adopted by the European Union and has been prepared on a going concern basis as described further below. a. Accounting policies The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are those as set out in the Group’s financial statements for the year ended 30 June 2020. In addition, tax on income in the interim period is calculated as described in note 5. New accounting standards and interpretations There have not been any new standards or interpretations adopted in the period which would have a material financial impact on, or disclosure requirement for, the Group’s interim report. b. Going concern The directors have prepared the interim financial statements on a going concern basis. In considering going concern, the directors have considered the Group’s forecasts and projections, taking account of reasonably possible changes in trading performance, including the possible effects of COVID-19. These show that the Group should be able to operate within the limits of its available resources. Accordingly, the directors have a reasonable expectation that the Group has adequate resources to continue in operation for the foreseeable future and a period of not less than twelve months from the date of this report. Accordingly, the going concern basis has been adopted in preparing the interim financial report. c. Adjusted performance measures Adjusted performance measures are used by the Directors and management to monitor business performance internally and exclude certain cash and non-cash items which they believe are not reflective of the normal day-to-day operating activities of the Group. The Directors believe that disclosing such non-IFRS measures enables a reader to isolate and evaluate the impact of such items on results and allows for a fuller understanding of performance from year to year. Adjusted performance measures may not be directly comparable with other similarly titled measures used by other companies. A detailed reconciliation between reported and adjusted measures is presented in note 4. Notes to the interim financial statements (continued) For the six-month period ended 31 December 2020 3. Operating segments The Directors consider that there is only one core business activity and there are no separately identifiable business segments which are engaged in providing individual products or services or a group of related products and services which are subject to separate risks and returns. The information reported to the Group’s Chief Executive Officer, who is considered the chief operating decision maker, for the purposes of resource allocation and assessment of performance, is based wholly on the overall activities of the Group. The Group has therefore determined that it has only one reportable segment under IFRS 8 Operating Segments, which is ‘sales of antibodies and related products’. The Group’s revenue and assets for this one reportable segment can be determined by reference to the Group’s income statement and balance sheet. Geographical information Revenues are attributed to regions based primarily on customers’ location. The Group’s revenue from external customers is set out below: Six months ended 31 Dec 2020 £’m Six months ended 31 Dec 2019 £’m The Americas 58.6 59.7 EMEA (i) 40.2 34.9 China 27.4 23.8 Japan 9.9 9.4 Rest of Asia (i) 11.4 10.4 147.5 138.2 (i) Revenues for the sub-region of Central Asia have been reclassified from EMEA to Rest of Asia for the six months ended 31 December 2020. This is to better align our data reporting to sales performance and geographical location. The value attributable to Central Asia for the six months ended 31 December 2020 is £0.6m (2019: £0.8m) and the comparatives presented have not been updated for this change. Revenue by type is shown below: Six month ended 31 Dec 2020 £’m Six months ended 31 Dec 2019 £’m Catalogue revenue 139.0 130.6 Custom products and services 2.7 3.3 IVD 2.6 1.4 Royalties and licenses 3.2 2.9 Custom products and licensing 8.5 7.6 Total reported revenue 147.5 138.2 Notes to the interim financial statements (continued) For the six-month period ended 31 December 2020 4. Adjusted performance measures A reconciliation of the Group’s adjusted performance measures to reported IFRS measures is presented below: Six months ended 31 Dec 2020 (unaudited) Six months ended 31 Dec 2019 (unaudited) Note Adjusted £m Adjusting items £m Total £m Adjusted £m Adjusting items £m Total £m Operating profit 23.6 (8.1) 15.5 33.4 (6.8) 26.6 Finance income 0.2 — 0.2 0.5 — 0.5 Finance costs (1.9) — (1.9) (1.1) — (1.1) Profit before tax 21.9 (8.1) 13.8 32.8 (6.8) 26.0 Tax 5 (3.9) 1.8 (2.1) (5.8) 5.9 0.1 Profit for the period 18.0 (6.3) 11.7 27.0 (0.9) 26.1 Six months ended 31 Dec 2020 (unaudited) £m Six months ended 31 Dec 2019 (unaudited) £m Analysis of adjusting items System and process improvement costs (i) (1.8) (2.1) Acquisition costs (ii) — (1.3) Integration and reorganisation costs (iii) (1.9) — Amortisation of acquisition related intangible assets (iv) (4.4) (3.4) Affecting operating profit and profit before tax (8.1) (6.8) Affecting tax Tax effect of adjusting items 1.8 1.2 Credit arising from patent box claims (v) — 4.7 1.8 5.9 Total adjusting items (6.3) (0.9) (i) Comprises costs of the ERP implementation which do not qualify for capitalisation. Such costs are included within selling, general and administrative expenses. (ii) Comprises legal and other professional fees associated with the acquisition of the Expedeon business. Such costs are included within selling, general and administrative expenses. (iii) Integration and reorganisation costs relate partly to the integration of the acquired Expedeon business (comprising mainly retention and severance costs as well as employee backfill costs for those involved in the integration and consultancy costs)and reorganisation costs in respect of alignment of the Group’s operational structure and geographical footprint to its strategic goals. Included within these costs are £0.6m of depreciation costs. Such costs are included within selling, general and administrative expenses. (iv) £3.2m (2019: £2.2m) of amortisation of acquisition intangibles is included within research and development expenses, with the remaining £1.2m (2019: £1.2m) included within selling, general and administrative expenses. (v) Comprises a one-off credit for historical periods in respect of the initial recognition of benefit from the lower rate of tax applied to profits on patented income under HMRC’s ‘patent box’ regime following successful registration of patents during the period. Notes to the interim financial statements (continued) For the six-month period ended 31 December 2020 5. Income tax The major components of the income tax (credit) / expense in the income statement are as follows: Six months ended 31 Dec 2020 (unaudited) £m Six months ended 31 Dec 2019 (unaudited) £m Current tax 3.3 — Deferred tax (1.2) (0.1) Total income tax charge / (credit) 2.1 (0.1) Adjusted income tax charge* 3.9 5.8 * Adjusted income tax charge excludes the tax effects of adjusting items as set out in note 4. The UK corporation tax rate for the six months ended 31 December 2020 was 19.0% (six months ended 31 December 2019: 19.0%). Effective tax rates represent management’s best estimate of the average annual effective tax rate on reported or adjusted profits with these rates being applied to half year results. The estimated effective rate of tax on reported profits for the full year ending 30 June 2021 is approximately 15.4% (year ended 30 June 2020 48.8%), representing management’s best estimate of the average annual effective tax rate on profits expected for the full year. The effective rate on adjusted half year profits is 17.8% and for the full year ending 30 June 2021 is expected to be approximately 18.0% (year ended 30 June 2020: 18.0%). 6. Earnings per share The calculation of earnings per ordinary share (EPS) and adjusted earnings per ordinary share (adjusted EPS) are based on profit after tax, and adjusted profit after tax, respectively, attributable to owners of the parent and the weighted number of shares in issue during the six-month period. Adjusted EPS figures have been calculated based earnings before adjusting items which are considered significant in nature or value and which are described in note 4. Six months ended 31 Dec 2020 (unaudited) £m Six months ended 31 Dec 2019 (unaudited) £m Profit attributable to equity shareholders of the parent - adjusted 18.0 27.0 Adjusting items (6.3) (0.9) Profit attributable to equity shareholders of the parent – total reported 11.7 26.1 Million Million Weighted average number of ordinary shares in issue 220.0 205.8 Less ordinary shares held by Equiniti Share Plan Trustees Limited (0.4) (0.5) Weighted average number of ordinary shares for the purposes of basic EPS 219.6 205.3 Effect of potentially dilutive ordinary shares: – share options and awards 2.4 1.9 Weighted average number of ordinary shares for the purposes of diluted EPS 222.0 207.2 Notes to the interim financial statements (continued) For the six-month period ended 31 December 2020 6. Earnings per share (continued) Basic EPS and adjusted EPS are calculated by dividing the earnings attributable to the equity shareholders of the parent by the weighted average number of shares outstanding during the year. Diluted EPS and adjusted diluted EPS are calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all potentially dilutive ordinary shares. Such potentially dilutive ordinary shares comprise share options and awards granted to employees where the exercise price is less than the average market price of the Company’s ordinary shares during the period and any unvested shares which have met, or are expected to meet, the performance conditions at the end of the reporting period. Six months ended 31 Dec 2020 (unaudited) Six months ended 31 Dec 2019 (unaudited) Basic EPS 5.3p 12.7p Diluted EPS 5.3p 12.6p Adjusted basic EPS 8.2p 13.2p Adjusted diluted EPS 8.1p 13.0p 7. Issue of share capital On 26 October 2020, the Group closed its offering of an aggregate of 10,287,000 American Depositary Shares ("ADSs") representing 10,287,000 ordinary shares at a price of $17.50 per ADS, following the Group’s secondary listing on Nasdaq. The net proceeds from this offering, net of issue costs of £2.1m, were £126.5m. In addition, £0.5m of proceeds from the issuance of share options and awards to employees were received during the period. 8. Notes to the cash flow statement Six months ended 31 Dec 2020 (unaudited) £m Six months ended 31 Dec 2019 (unaudited) £m Operating profit for the period 15.5 26.6 Adjustments for: Depreciation of property, plant and equipment 4.3 3.4 Depreciation of right-of-use assets 3.8 3.0 Amortisation of intangible assets 7.9 6.8 Loss on disposal of property, plant and equipment 0.2 — Derivative financial instruments at fair value through profit or loss (0.4) (0.7) Research and development expenditure credit (0.7) (0.9) Share-based payments charge 7.3 5.0 Unrealised currency translation gains 1.0 (1.9) Operating cash flows before movements in working capital 38.9 41.3 Increase in inventories (4.0) (4.6) (Increase) / decrease in receivables (7.7) 7.1 Increase in payables 6.5 1.7 Cash generated from operations 33.7 45.5 9. Dividend Six months ended 31 Dec 2020 (unaudited) £m Six months ended 31 Dec 2019 (unaudited) £m Amounts recognised as distributions to equity shareholders in the period: Final dividend for the year ended 30 June 2019 — 17.7 Notes to the interim financial statements (continued) For the six-month period ended 31 December 2020 10.Financial instruments and risk management The Group’s activities expose it to a variety of financial risks that include currency risk, interest rate risk, credit risk and liquidity risk. The condensed interim financial statements do not include all financial risk management information and disclosures required in the annual financial statements; accordingly, they should be read in conjunction with the Group’s financial statements for the year ended 30 June 2020. There have been no changes to the risk management policies since the year ended 30 June 2020. The table below analyses financial instruments carried at fair value by valuation method. The different levels have been defined as follows: Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable market inputs). The following table presents the Group’s assets and liabilities carried at fair value by valuation method. 31 December 2020 Level 1 £m Level 2 £m Level 3 £m Total £m Assets Derivative financial instruments — 0.3 — 0.3 Investment 1.2 — 1.9 3.1 Total assets 1.2 0.3 1.9 3.4 Liabilities Derivative financial instruments — (0.1) — (0.1) Total liabilities — (0.1) — (0.1) 30 June 2020 Level 1 £m Level 2 £m Level 3 £m Total £m Assets Derivative financial instruments — — — — Investment 4.8 — 1.9 6.7 Total assets 4.8 — 1.9 6.7 Liabilities Derivative financial instruments — (1.2) — (1.2) Total liabilities — (1.2) — (1.2) There were no transfers between levels during the period. The Group’s Level 2 financial instruments consist of forward foreign exchange contracts fair valued using forward exchange rates that are quoted in an active market. The Group continues to generate significant amounts of US Dollars, Euros, Japanese Yen and Chinese Renminbi in excess of payments in these currencies and has hedging arrangements in place to reduce its exposure to currency fluctuations. Notes to the interim financial statements (continued) For the six-month period ended 31 December 2020 10. Financial instruments and risk management (continued) The following table details the forward exchange contracts outstanding as at the period end: Maturing in US Dollars Euros Japanese Yen Chinese Renminbi Sell $m Average rate Sell €m Average rate Sell ¥m Average rate Sell ¥m Average rate Period ending 30 June 2021 1.0 1.30 9.2 1.11 520.0 136.5 28.0 9.0 Year ending 30 June 2022 0.2 1.30 4.3 1.10 204.0 137.3 12.0 9.0 The Group’s Level 3 financial instruments consist of unlisted equity shares. The fair value of the unquoted equity shares can be determined as management monitors the ongoing performance of the investment. Borrowings On 23 November 2020, the Group repaid in full the sum of £107.0m which was drawn under its Revolving Credit Facility (RCF). 11. Capital commitments As at 31 December 2020, the Group had capital commitments of £8.9m (31 December 2019: £1.7m) relating to the acquisition of property, plant and equipment and intangible assets. 12. Post balance sheet event On 7 January 2021, the Company received approval from all syndicate banks for a two year extension to its Revolving Credit Facility (RCF) following the exercise of an extension option on 17 December 2020. This extends the expiry of the facility to 31 January 2024. All other terms of the facility remain unchanged. Risks and uncertainties The principal risks and uncertainties which the Group faces in the undertaking of its day-to-day operations and in pursuit of its longer-term objectives are set out in the Annual Report and Accounts 2020 on pages 52 to 57 and in note 4 to the consolidated financial statements. Information on financial risk management is set out in note 26 to the consolidated financial statements. A copy of the Annual Report and Accounts is available on the Group's website The principal risks and risk pro the Group have not changed over the interim period and are not expected to change over the next six months. As noted in the Annual Report and Accounts 2020, the Group continues to monitor developments in respect of the UK’s withdrawal from the EU and the consequences of how these might affect the business. The principal risks remain as: Principal risk Description and relevance 1. Competition and customer The risk of competitors introducing new technologies, channels or workarounds, strengthening product offerings and routes to market. 2. Acquisitions and integrations Risks include overvaluation of targets, failing to identify issues or risks in due diligence or failing to integrate acquired operations or technologies effectively in order to realise the benefits. There is also a risk of failure to identify and acquire businesses which could bring added value. 3. People and resources The risk of failure to recruit and develop people at the right rate to support Abcam’s strategy, failing to maintain an engaged and motivated workforce or to provide the tools and resources for employees to do their work effectively. 4. Transformation projects The risk of failure to deliver on Abcam’s transformational growth projects, including our ongoing ERP implementation and reinvention of the digital channel. 5. Cyber security and IT infrastructure The risk that Abcam fails to operate IT systems, software and hardware that are sufficiently effective, reliable and robust to support the business in its operations, or that Abcam’s critical IT infrastructure is compromised or subject to cyber attack. 6. Geopolitical/economic disruption and research funding The risk of unfavourable geopolitical or economic changes, including the risk of a substantial reduction in funding for life sciences research in one of Abcam’s significant territories 7. Business continuity The risk that a disruptive event or disaster occurs at a key facility, impacting our ability to serve customers. 8. Laws, regulations, legislation and compliance Failure to comply with legislation and regulation in the markets and countries in which Abcam operates. 9. Ethical business and CSR The risk of not meeting high standards of quality and ethical business practice.

New York, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Smart Inhalers Market to 2027 - Regional Analysis and Forecasts by Product; Disorder; End User, and Country" - However, risks associated with cyber threats with smart inhalers are likely to pose a negative impact on the market growth. On the other hand, development of growth in the Europe healthcare market is likely to have a positive impact on the growth of the Europe smart inhalers market in the coming years. With rapid urbanization there has been growth in various adverse factors that have led to the growth of respiratory diseases across the Europe. Some of the factors leading to growth in the number of asthma and COPD cases across the Europe are rise in air pollution levels and increasing smoking habits. The rise in air pollution levels has been a matter of rising concern in developed as well as developing economies.As per data published by the World Health Organization (WHO) released during May 2018, 9 out of 10 individuals are believed to breathe air containing high levels of pollutants. Data published by WHO reveals that approximately 7 million people die every year due to exposure to fine particles present in polluted air, which penetrate deep into lungs and the cardiovascular system.This leads to various diseases such as lung cancer, pneumonia, chronic obstructive pulmonary diseases and respiratory infections, among others. Studies reveal, above 90% of air pollution-related deaths worldwide occur in low- and middle-income countries of the Eastern Mediterranean, European regions.According to world health organization (WHO), about 21,000 premature deaths per year in European region because of air pollution like Ozone pollution courses breathe difficulties, triggers asthma symptoms, and causes lung and heart diseases. Additionally increasing indirect effects of air pollution like growing climate change, because of transport is the fastest growing source of fossil-fuel emissions of carbon dioxide (CO2) which is a largest contributor of the climate change. As per data published by World Health Organization (WHO) Some 40 million people in the 115 largest cities in the European Union (EU) are exposed to air exceeding WHO air quality guideline values for at least one pollutant. Children that live close by the traffic of heavy duty vehicle have a high risk of respiratory then those living near less congested streets. Hence, the rising levels of air pollution coupled is anticipated to drive the demand for smart inhalers market during the forecast period. In 2018, the inhalers segment held a largest market share of the smart inhalers market, by product.The inhalers is expected to dominate its market share in 2027 owing to the increasing mortality rate of asthma. The inhalers segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027. Home-care setting segment a largest market share of the smart inhalers market, by end user in 2018.This segment is also expected to dominate the market in 2027. As smart inhaler devices are connected digitally, enabling the patients to get advice from their physicians, even when situated far away. Home-care setting segment is also expected to grow at the fastest growth rate during the forecast period, 2019 to 2027. Some of the major primary and secondary sources for smart inhalers included in the report are, GlaxoSmithKline plc, Adherium Ltd., Vectura Group plc, Novartis AG, Findair Sp. z o. o., Cohero Health, Crux Product Design Ltd, Teva Pharmaceuticals, 3M, Amiko Digital Health Limited, and others. Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001